

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A web-based intervention to reduce psychological barriers to insulin therapy among adults with non-insulin-treated type 2 diabetes: study protocol for a two-armed randomised controlled trial of 'Is Insulin Right for Me?'

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-051524
Article Type:	Protocol
Date Submitted by the Author:	22-Mar-2021
Complete List of Authors:	Holmes-Truscott, Elizabeth; Deakin University, School of Psychology; Diabetes Victoria, The Australian Centre for Behavioural Research in Diabetes Holloway, Edith; Deakin University, School of Psychology; Diabetes Victoria, The Australian Centre for Behavioural Research in Diabetes Husin, Hanafi; Deakin University, School of Psychology; Diabetes Victoria, The Australian Centre for Behavioural Research in Diabetes Furler, John; University of Melbourne, Department of General Practice Hagger, Virginia; Deakin University, School of Nursing and Midwifery Skinner, Timothy; La Trobe University, Rural Health School; University of Copenhagen, Department of Psychology Speight, Jane; Deakin University, School of Psychology; Diabetes Victoria, The Australian Centre for Behavioural Research in Diabetes
Keywords:	DIABETES & ENDOCRINOLOGY, Clinical trials < THERAPEUTICS, SOCIAL MEDICINE

SCHOLARONE™
Manuscripts

1
2
3 **Target journal:** BMJ open
4

5 **Article type:** Research article - Clinical
6

7 **Title:** A web-based intervention to reduce psychological barriers to insulin therapy among adults
8 with non-insulin-treated type 2 diabetes: study protocol for a two-armed randomised controlled trial
9 of '*Is Insulin Right for Me?*'
10

11 **Running title:** Reducing barriers to insulin: randomised control trial protocol
12

13 **Protocol number, version, date:** SA-2017-11697; V2.2e 16 June 2020
14

15 **Authors:**
16

17 Dr Elizabeth Holmes-Truscott^{1,2}, Dr Edith E Holloway^{1,2}, Mr Hanafi M Husin^{1,2}, Associate Prof John
18 Furler³, Dr Virginia Hagger⁴, Prof Timothy Skinner^{2,5,6} and Prof Jane Speight^{1,2},
19

20 **Affiliations:**
21

- 22 1. School of Psychology, Deakin University, Geelong, Victoria, Australia
- 23 2. The Australian Centre for Behavioural Research in Diabetes, Diabetes
24 Victoria, Melbourne, Victoria, Australia
- 25 3. Department of General Practice, The University of Melbourne, Carlton, Victoria, Australia
- 26 4. School of Nursing and Midwifery, Faculty of Health, Deakin University, Burwood, Victoria,
27 Australia
- 28 5. La Trobe Rural Health School, La Trobe University, Victoria, Australia
- 29 6. Department of Psychology, University of Copenhagen, Copenhagen, Denmark
30
31
32
33
34
35

36 **Corresponding author:**
37

38 Dr Elizabeth Holmes-Truscott
39 etruscott@acbrd.org.au
40 570 Elizabeth Street Melbourne 3000 Vic Australia
41
42

43 Total word count: 3991 (max:4000)

44 Table/figures: 2

45 Abstract: 250 (max 250)

46 References:
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction Psychological barriers to insulin therapy are associated with the delay of clinically indicated treatment intensification for people with type 2 diabetes (T2D), yet few evidence-based interventions exist to address these barriers. We describe the protocol for a randomised controlled trial (RCT) examining the efficacy of a novel, theoretically-grounded, psycho-educational, web-based resource designed to reduce psychological barriers to insulin among adults with non-insulin treated T2D: *“Is insulin right for me?”*.

Methods and analysis Double-blind, parallel group RCT. A target sample of N=392 participants (n=196/arm) will be randomised (1:1) to *“Is insulin right for me?”* (intervention) or widely available online resources (control). Eligible participants include adults (18-75 years), residing in Australia, currently taking oral hypoglycaemic agents to manage T2D. They will be primarily recruited via invitations and reminders from the national diabetes registry (from a purposefully selected sample of N≥12,000). Exclusion criteria: experience of self-administered injectable; previously enrolled in pilot RCT; *“very willing”* to start insulin as baseline. Outcomes will be assessed via online survey at two weeks and six months. Primary outcome Between-group: difference in mean negative insulin treatment appraisal scores (ITAS Negative) at two-week and six-month follow-up. Secondary outcomes: Between-group differences in mean positive insulin appraisals (ITAS Positive) and percentage difference in intention to commence insulin at follow-up time-points. All data analyses will be conducted according to the intention-to-treat principle.

Ethics and dissemination Deakin University Human Research Ethics Committee (2020-073). Dissemination via peer-reviewed journals, conferences and a plain-language summary.

Trial registration Australian and New Zealand Clinical Trials Registry ACTRN12621000191897

Strengths and limitations of this study

- *‘Is insulin right for me?’* is the first self-directed, theoretically-grounded web-based intervention targeting salient psychological barriers to insulin.
- This fully-powered randomised controlled trial will provide evidence of the impact and acceptability of *‘Is insulin right for me?’*, to reduce negative insulin appraisals among adults with non-insulin-treated type 2 diabetes (T2D) and increase intention to initiate insulin.
- Limitations include the self-selected sample which may lead to an under-representation of those hardest to reach or most at need (i.e. those not at all willing to commence insulin).
- If effective at changing attitudes and intentions, then examination of the intervention's impact on actual timely insulin uptake and feasibility of implementation within clinical care will be warranted.

Introduction

Type 2 diabetes (T2D) is a progressive condition that requires timely adjustment of treatment to achieve and maintain optimal glucose outcomes (1-3), and prevent or delay the onset of micro and macrovascular complications (4, 5). A staged approach to pharmacological management of glucose in T2D is recommended (1-3), including early consideration and initiation of insulin where glycaemic outcomes are above target (typically HbA1c >7%,53 mmol/mol (2)) despite maximal dose of non-insulin medicines. However, vast literature suggests that treatment adjustment, including insulin initiation, is often delayed well beyond the point of clinical need (6, 7). For example, a large-scale (N=>80,000), retrospective study conducted in the UK, identified HbA1c at insulin initiation for people with T2D was ≥8.7% (72 mmol/mol) with a median time until insulin initiation of ≥6 years (8). Finally, a recent Australian primary care based prospective study identified that, among adults with T2D for whom insulin was clinically indicated (HbA1c ≥7.5%/58mmol/mol, with maximal oral therapy), receiving usual care, only 31% had initiated insulin within 24 months (9, 10).

Reasons for the delay of treatment intensification are multifaceted (7, 11, 12), and effective interventions targeting barriers to insulin use are required (13-15). At a systemic or health professional level, promising results have been shown using multi-disciplinary models of care (e.g. an enhanced practice nurse role within primary care setting (9)), effective consultation strategies (e.g. collaborative approach to care (16)), and insulin-specific structured education programs (17, 18). However, there is a parallel need for interventions which directly target the psychological barriers (negative beliefs and attitudes) to insulin held by the person with T2D. Our prior research demonstrated, independent of an optimised model of primary care ('stepping up'), attitudes toward insulin were associated with hypothetical willingness to initiate insulin, which, in turn predicted actual insulin use 12 months later (14, 19). Elsewhere, qualitative research with people with T2D attending an insulin-specific education program identified an unmet need for psychological barriers to insulin to be addressed appropriately (20). Furthermore, unaddressed negative insulin appraisals may have long-lasting impact on the optimal use of insulin and/or emotional wellbeing following insulin initiation (21-23). Such psychological barriers to insulin use include, for example, worries about performing injections, potential pain and side effects, as well as feelings of guilt and self-blame about the onset of the condition and/or the need for treatment progression (24).

Few evidence-based interventions targeting psychological barriers to insulin have been developed and fewer still are evaluated adequately, or implemented beyond research studies (17, 25, 26). Furthermore, preliminary data from relevant clinic-based and insulin starts group-education interventions suggest low intervention uptake among people with T2D (17, 26). In addition to common barriers to outpatient clinic and structured education program attendance discussed elsewhere (27, 28), this low uptake may be in part due to individuals concern that participation would lead to insulin acceptance (26). Furthermore, health professionals report limited time and resources to facilitate insulin starts (12), and express concerns about the added burden of intervention delivery on their already limited time (26). Effective interventions that complement clinical care (but are not reliant on a health professional for delivery) have the potential to be acceptable to both people with T2D and their health professionals.

Given the sheer size of the population with T2D, the potential for scalable implementation is also an important consideration. The internet may be an ideal platform to reach those with T2D with concerns about insulin, as it also allows for anonymity in information seeking. One third of Australian adults with T2D and suboptimal HbA1c report seeking online health information in a past 12 period (29). Further, online interventions for the management of T2D with clear theoretical groundings and

1
2
3 based on behaviour change techniques show favourable outcomes (30). While peak health bodies
4 publish resources online about T2D treatments, these materials are not typically theoretically
5 informed, do not use evidence-based behaviour change techniques (31, 32), and are rarely
6 developed in consultation with, or evaluated among, people with T2D. Further, these resources are
7 rarely targeted at addressing salient psychological barriers to treatment use.
8

9
10 In line with UK Medical Research Council (MRC) guidance for developing and evaluating complex
11 intervention, we developed a theoretically-grounded, psycho-educational, web-based resource for
12 people with non-insulin-treated T2D designed to reduce salient psychological barriers to insulin
13 therapy: '*Is insulin right for me?*' (33). A pilot study demonstrated feasibility of a two-arm
14 randomised controlled trial (RCT) design to test intervention efficacy, compared with widely
15 available online informational resources, as well as acceptability of the intervention among adults
16 with T2D (34).
17

18 This protocol describes the design of a double-blinded, parallel group, individually randomised
19 controlled trial (two-arms, 1:1 ratio), comparing '*Is insulin right for me?*' (intervention) with widely
20 available online text-based resources about insulin (control) among adults with non-insulin-treated
21 T2D. We hypothesise an immediate (two weeks) and sustained (six months) positive effect of the
22 intervention, compared to control, on negative insulin appraisals. We also expect the intervention to
23 be acceptable to users and to be associated with immediate and sustained improvement in positive
24 insulin appraisals and hypothetical willingness to begin insulin therapy.
25

26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Methods and analysis

Study setting

Participation in this Australian study, including provision of informed content, data collection and
intervention exposure, is completely online, using personal computers/mobile devices.

Participants and recruitment

Potential participants will be enrolled in the study only if they meet all the inclusion criteria and
none of the exclusion criteria. Inclusion criteria: aged 18 to 75 years; diagnosed with T2D; use of oral
hypoglycaemic agents (OHAs); able to read/write in English and capable of providing informed
consent; residing in Australia; access to an internet-enabled computer or tablet device for the
duration of the study. Exclusion criteria: diagnoses of diabetes other than T2D; current or prior
experience of self-administered injectable treatment for any illness or condition (including diabetes);
unable to read/write in English; unable to use/access internet-enabled devices; enrolled as a
participant in the pilot RCT (34); reports being "very willing" to initiate insulin therapy (measured
using a single-item "hypothetical willingness" questionnaire), i.e. rendering it impossible to record
improvement in this outcome measure.

The primary method of recruitment will be via invitation from the National Diabetes Services
Scheme (NDSS). In total, $\geq 12,000$ NDSS registrants (stratified by state) who have previously
consented to being contacted about research opportunities will be invited to take part either via
email ($n=10,000$) or postal mail ($n=2,000$) as per the registrants preferred method of contact. The
NDSS is an Australian government initiative, administered by Diabetes Australia. The NDSS registry
includes over 1.2 million Australians with T2D, and is considered to be one of the most
comprehensive and up-to-date diabetes prevalence datasets in Australian (35). The research team
will not have access to NDSS registrants' details unless they make contact/take part in the study, and
the NDSS will not be notified of participating registrants. The total number of invited registrants was
selected based on adoption of a conservative response rate of 8% (36), and an expected 46%
translation from consent to enrolled participant (as seen in the pilot RCT; (34)). Invited NDSS
registrants will receive an invitation reminder via e-mail or postal mail two weeks following first

1
2
3 contact. If our target sample size is not reached within four weeks of the initial invitation, a second
4 NDSS e-mail/mailout will be sent until our target sample size is reached or the two-month
5 recruitment period has concluded. The number of registrants contacted and method (e-mail vs. mail)
6 for subsequent recruitment efforts will be informed by the success rate from the original invitation
7 (i.e. percentage enrolled reporting hearing about the study via email or mail invitation). The study
8 will also be advertised online via the researchers' affiliated professional websites and social media
9 accounts, and a study flyer will be circulated to diabetes researcher and health professional
10 networks.
11
12

13 Study procedure

14 The schedule of enrolment, intervention and assessment is detailed in Figure 1. Study recruitment
15 will be open for a maximum of two months or until sample size (enrolled) is reached. Participation
16 (from study entry to exit) will be for a duration of six months. Study advertisements will direct
17 potential participants to the study website (hosted by Qualtrics™) to access the Plain Language
18 Statement, provide informed consent, and complete screening questions online. Eligibility will be
19 determined automatically based on responses. Eligible participants will be directed immediately to
20 complete an online baseline survey, and, following submission, will be allocated at random to one of
21 two study arms. Randomised participants will receive an email including details about how to access
22 the relevant online resources for their study arm. For participants allocated to the intervention
23 group, this will include a unique username and password enabling access to the resource (at their
24 convenience) within the following two-week period. One week following allocation, participants will
25 receive a reminder email to access/log into the resource. Participants will be sent an email with a
26 link to the online follow-up survey at two weeks and six months following baseline. The two-week
27 follow-up survey will be available for completion for two weeks, and the six-month follow-up survey
28 will be available for completion for three weeks. Study end-point for all participants will be marked
29 by either submission of the six-month follow-up survey (within 21 days of request), or non-
30 submission at 22 days following the survey request.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. Schedule of enrolment, interventions, and assessments.

TIMEPOINT		STUDY PERIOD			
		Enrolment	Post-allocation		
		Screening	Baseline	Two weeks	Six months
ENROLMENT:					
Informed consent		X			
Eligibility screen		X			
Randomisation			X		
INTERVENTIONS:					
Intervention: Is insulin right for me?			→		
Control			→		
ASSESSMENTS:					
Contact information	Name*, email address*	X		X	X
Pilot	Participation in the pilot study: yes/no*	X			
Recruitment	Referral method (e.g. NDSS invite)	X			
Demographics	Age*, gender*, country of residence*	X			
	Country of birth, primary language, relationship status, employment status, qualifications, postcode		X		
Diabetes	Diabetes type*, diabetes duration*, current diabetes management regimen*, prior use of self-administered injectable treatment*	X			
	Brand names of currently administered diabetes medications, most recent HbA1c (if known), frequency of self-monitoring of glucose (if any),		X		X
General health	Co-morbidities (kidney disease, retinopathy, neuropathy, heart disease, stroke, vascular disease, sexual dysfunction, other to be specified), weight and height		X		
Clinical discussion of insulin therapy	Recall of discussion/education about to insulin therapy in clinical setting; prior recommendation of insulin therapy by doctor		X		X

bmjopen-2021-051524 on 21 February 2022. Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

For peer review only

Previous information about insulin therapy	What information about insulin have you read		X		
Psychological insulin receptiveness	Hypothetical willingness to commence insulin (37)*	X		X	X
Attitudes towards insulin	Insulin Treatment Appraisal Scale: ITAS (38)		X	X	X
Knowledge	Diabetes-specific knowledge: Michigan Diabetes Research and Training Center's Revised Diabetes Knowledge Test: DKT-R (39)		X		
	Insulin-specific knowledge: Study specific items		X	X	X
Diabetes-specific distress	Problem Areas In Diabetes: PAID (40)		X	X	X
Illness perceptions	Brief Illness Perceptions Questionnaire: BIPQ (41)		X	X	X
Diabetes-specific self-efficacy	Confidence In (type 2) Diabetes Self-management scale: CIDS-2 (or insulin version at follow-up for participants commenced insulin (CIDS-1) (42)		X	X	X
Diabetes management satisfaction	Study specific item		X	X	X
Resource use and acceptability	Resource access (yes/no) <u>If no:</u> Reasons for not accessing <u>If yes:</u> User rating scale and feedback			X	
Further comments	Free-text box for participant to provide further feedback.			X	X

*compulsory questions for participation.

Randomisation and blinding

After baseline survey submission, participants will be stratified by gender and randomised to either the intervention or control arm using computer-generated, randomly permuted block sizes of four, six or eight. The randomisation sequence will be computer generated and the allocation will be fully concealed from both the investigators and participants. Upon randomisation, participants will receive an email from a researcher, independent of the study investigator team and who does not have access to the incoming survey data (except for participant ID, name, gender and email address), specifying access details to their allocated online resource. The statistician, participants, and investigator team will remain blinded to study arm allocation throughout data collection and analyses. The project manager (EEH), who will monitor incoming survey data, will be blinded from study arm allocation except where a participant self-identifies study arm allocation within the follow up surveys (e.g. in a free-text response box). Any breaches will be recorded and reported with the main findings.

Intervention

Intervention group participants will receive access to a novel psycho-educational web-based resource '*Is insulin right for me?*'. The intervention was developed using a systematic process grounded in behaviour change theory and has been described elsewhere (33). In brief, eight salient psychological barriers to insulin therapy were identified via literature search. Each barrier (i.e., determinant of behaviour) was mapped to relevant domains of the Theoretical Domains Framework (TDF) (43). Determinants were then mapped onto behaviour change techniques (BCTs) considered relevant to overcoming the modifiable barriers (32, 43). Content responding to each barrier was developed by the investigator team (experts in health psychology, primary care medicine and diabetes education) and refined following consumer feedback (cognitive debriefing interviews, n=6) and external expert peer review (n=5) to ensure relevance for people with T2D and clinical accuracy.

The eight barriers targeted in the '*Is insulin right for me?*' resource are phrased as common questions, with one barrier/question per website page (See Table 1). The resource home page lists all eight barriers/questions as well as a preview (a key summary statement that responds to the question and content overview). For each barrier, each active intervention is presented on a separate webpage, (200-500 words; 5-minute read) to facilitate user engagement. In addition, the resource includes information about the key benefits of insulin therapy: (1) that it lowers blood glucose levels; (2) can lower your risk of long-term health complications; (3) can make you feel better; and (4) can make managing your diabetes more flexible. The lesser focus on benefits than barriers is due to the evidence that most people with T2D experience / report barriers to insulin therapy despite endorsing benefits (14, 19). Finally, the resource also provides links to other resources about T2D and insulin available from the NDSS, and study information.

Table 1. Description of the eight barriers targeted in the '*Is insulin right for me?*' resource

Barrier (Question)	Resource aim (using behaviour change theory)	Format of delivery
Does insulin mean my diabetes is more serious?	<ul style="list-style-type: none"> Challenge beliefs: Insulin therapy can be clinically recommended at any time Shape knowledge: Provide information about the role of insulin Motivate: Diabetes is always serious 	Interactive quiz; video depicting progressive nature of T2D (imagery and text), imagery and personal quote

1 2 3 4 5 6 7 8 9	Do insulin injections cause complications?	<ul style="list-style-type: none"> • Shape knowledge: Provide information about diabetes complications risk factors • Motivate: Acknowledge where this belief comes from. Validate concerns 	Text; imagery and personal quote
10 11 12 13 14 15 16 17 18	Is it my fault I need to inject insulin?	<ul style="list-style-type: none"> • Identification of self as role model: 'You are doing this for yourself, insulin is a good thing' • Restructuring the social environment: being prepared for how others may react • Encouragement and support: Sharing how you feel with others 	Text; case study (with audio recording); statistic; and personal quote
19 20 21 22 23 24 25 26 27 28	Will I gain weight?	<ul style="list-style-type: none"> • Shaping knowledge: Many people gain a small amount of weight when they commence insulin therapy. There are things that you can do to prevent unhealthy weight gain • Motivate: Acknowledge and validate fear • Salience of side effect: for many, weight gain is small 	Interactive quiz; text; imagery and personal quote
29 30 31 32 33 34 35 36 37 38	Will injecting hurt?	<ul style="list-style-type: none"> • Shaping beliefs: Dispel myths • Manage expectations: Information and strategies to alleviate and minimise discomfort • Demonstration: of a person injecting insulin • Encouragement: to discuss insulin therapy and any concerns with a health professional • Imagery: small/fine needles & site of the injection 	Text; demonstration of injecting insulin; imagery and personal quote
39 40 41 42 43 44 45 46	What about hypos?	<ul style="list-style-type: none"> • Shape knowledge: Frequency/severity of hypos • Motivate: Acknowledge/validate fears 'having concerns about hypos is natural'. • Reduce emotional valence of the fear: Low risk of having a severe hypo. Support is available 	Interactive quiz; text; imagery and personal quote
47 48 49 50 51 52 53 54	Will injecting insulin be a burden?	<ul style="list-style-type: none"> • Increase knowledge: You can take insulin with you wherever you go • Increase self-efficacy: The changes you need to make are minimal and you can handle them. • Weigh pros versus cons: Insulin can make management of diabetes easier 	Text and personal quote
55 56 57 58 59 60	What will others think of me?	<ul style="list-style-type: none"> • Identification of self as role model: 'You are doing this for yourself, insulin is a good thing' • Restructuring the social environment: being prepared for how others may react 	Case studies with examples (with audio recording); text; and personal quote

	<ul style="list-style-type: none"> • Encouragement and support: Start a 'safe' conversation to share how you feel with others 	
--	--	--

Control group

Control arm participants will be directed to a static webpage including links to publicly available text-based NDSS factsheets, including: "Insulin" and "Medication for type 2 diabetes". The control group webpage also includes links to further information about the study and research team (consistent with intervention arm).

Outcomes

The co-primary outcome measure are the difference in mean negative insulin appraisals, as measured by the Insulin Treatment Appraisal Scale (ITAS) Negative subscale score (38), between the intervention and control arm at two-week and six-month follow-up, adjusted by baseline scores. We hypothesise that, at two weeks, a statistically significant difference in mean ITAS Negative scores of ≥ 4 points (approximately 0.5 standard deviations) will be observed between the intervention and control arm, favouring the intervention arm; and that this difference will be sustained at six months.

Our secondary outcome measures are immediate and sustained between-arm differences in: a) positive insulin appraisals, as measured by ITAS Positive subscale score (38); and b) hypothetical willingness to begin insulin therapy, as measured by a single item (37). We hypothesise that, at two weeks and six months, a statistically significant between-group difference will be observed in:

1. mean ITAS Positive scores, adjusted for baseline scores, favouring the intervention arm;
2. the percentage of participants who respond 'not at all willing' (hypothetical willingness item). The intervention arm will be less likely to be 'not at all willing' compared to controls.

The following survey data will be examined by study arm for process evaluation purposes:

1. Clinical discussion and recommendation of insulin therapy, change in medications, and satisfaction with diabetes management at six-month follow up
2. Change in secondary psychosocial outcome scores at two-week and six-month follow up: diabetes-specific distress (PAID) (40), illness perceptions (BIPQ) (41), diabetes-specific self-efficacy (CIDS) (42), study-specific insulin-related knowledge questionnaire.
3. Diabetes-specific knowledge at baseline (DKT-R) (39).
4. Study-specific resource use and acceptability (study specific items) as two-week follow up.

Figure 1 details the self-reported demographic, clinical, psychosocial, and study-specific data to be collected and the time-points at which they are to be collected. In addition, website analytics data will be collected to assess protocol fulfilment with the intervention resource (i.e. proportion of 'enrolled' participants who accessed the '*Is insulin right for me?*' website at least once). Various analytics (e.g. average number of online resource visits; time (minutes) spent on online resource; most commonly (frequency, %) viewed pages) will be examined to explore any relationship(s) between type/duration of content accessed and the study outcomes. Finally, number of views and average time spent watching two videos embedded in the intervention resource will be captured via YouTube.

Sample size

A minimum sample size of N=250 (n=125 per arm) is required to detect a minimally important difference of half a standard deviation in ITAS Negative Scores (38) between study arms, at 85%

1
2
3 power and 0.05 significance level using a two-sided test. Assuming a 20% attrition rate at two weeks
4 (34) and a further 20% attrition at six months, the targeted sample size inflates to approximately
5 $N=392$ ($n=196$ per arm). Overall, a 40% attrition rate is incorporated into our estimated sample size
6 and replacements will not be made for losses to follow-up.
7
8

9 Data collection, management and analysis

10 Participant-reported data will be collected online via Qualtrics™, hosted through the Deakin
11 University secure network. Consent, eligibility screening and baseline survey data will be collected in
12 a single sitting (directed via study advertisement link), and an email will provide enrolled participants
13 with a link to online follow-up surveys. The intervention website will require participant log-in,
14 allowing for automatic collection of website usage data for each intervention participant via Google
15 Analytics.
16
17

18 To improve participant retention and protocol compliance, trial participants will receive reminder
19 emails to access/view the allocated online resource (sent to all participants two weeks following
20 allocation. In addition, reminder emails will be sent at one week (and two weeks for six-month time-
21 point) to participants who have yet to commence their online follow-up surveys. To aid recruitment
22 and retention, participants who complete all three surveys (the baseline, two-week *and* six-month
23 follow-up) will be entered into a prize draw to win one of 20 \$100 e-gift vouchers.
24
25

26 Participants who do not access their allocated resource(s) will still be followed up until the end of
27 the trial unless they withdraw from the trial. Participants who do not complete the two-week follow
28 up survey will have 'missing data' at two weeks, but remain eligible to complete the six-month
29 follow up survey. Participants who do not complete the six-month follow up survey within three
30 weeks of receipt will have 'missing data' at six months. Participants with missing data at both follow-
31 up time-points will be deemed 'lost to follow-up'.
32
33

34 Study data collected from withdrawn participants will be deleted, with the exception of basic de-
35 identified sample characteristics (gender, age, diabetes duration), trial arm allocation, timing of
36 withdrawal, and reason for withdrawal, where applicable.
37
38

39 Data storage

40 At study conclusion, survey data and website usage data (for intervention participants only) will be
41 downloaded from Qualtrics and Google Analytics, respectively, and linked according to participant
42 ID. Identifiable information (email, name) will be separated from study data and stored along with
43 participant ID number in a password-encrypted excel spreadsheet. All data will be stored in a secure
44 electronic file accessible only by the research team. In accordance with clinical trial regulations, data
45 will be kept for a minimum of 15 years after study completion and then disposed by erasing of
46 electronic files.
47
48

49 Statistical methods

50 Quantitative data analyses will be performed using Stata/SE 16.0 and/or IBM SPSS 26. Descriptive
51 statistics will be used to describe participant baseline characteristics and psychological outcomes at
52 each time point. Participant characteristics at baseline will be visually assessed by allocation for
53 imbalance. The overall characteristics of the study cohort will be compared to those lost to follow-
54 up.
55
56

57 An intention-to-treat (ITT) approach will be adopted whereby participants will be analysed according
58 to the arm they were allocated to, and all participants will be included in the analysis. A linear mixed
59 effects model will be used to estimate the difference in mean ITAS Negative scores between arms at
60

1
2
3 two weeks and six months using restricted maximum likelihood estimation. Treatment arm and all
4 three time-points (baseline, two weeks and six months) will be included as fixed effects in the
5 model. Random effects will be used to account for repeated participant measures. The outcome
6 measure will be adjusted by the stratification factor (gender), as well as age, diabetes duration and
7 education should these be imbalanced between the arms at baseline.
8
9

10 ITAS Positive Scores (secondary outcome), and continuous psychosocial process evaluation
11 outcomes (e.g. PAID, BIPQ, CIDS) will be analysed using the same modelling approached described
12 above. An ordinal logistic mixed effects model will be used to quantify between-arm differences in
13 the willingness to begin insulin therapy (secondary outcome) at the various time points.
14

15 Generalised linear mixed effects models assume any missing data are missing at random. This
16 assumption will be tested in a sensitivity analyses whereby a pattern mixture model will be used to
17 determine whether study conclusions would change should the missing data not be missing at
18 random.
19

20
21 Descriptive data will be used to explore trends in protocol fulfilment, website analytics and
22 acceptability data, as well as medication changes and clinical discussion of insulin therapy at six
23 months separately for each study arm.
24

25 26 Monitoring

27 Co-authors EHT and JS are the responsible investigators and will oversee the research project.
28 During recruitment and data collection, the number of potential participants consenting, eligible and
29 enrolled as well as dates of all participant encounters (i.e. enrolment; intervention access &
30 reminder emails; survey access, reminder and closure) and survey completion will be monitored by
31 EEH and communicated to investigator team. The primary funding body will be allowed access to all
32 de-identified data from the study for audit purposes, if requested.
33
34

35 This research protocol does not include administration or manipulation of, or investigation of the
36 effects of, any pharmacological or therapeutic goods. However, in line with the pharmacovigilance
37 reporting requirements of the funding body, all survey data collected will be screened for adverse
38 events that may be associated with the funding body's products and, in the event of the research
39 team becoming aware of a potential adverse event, participants will be contacted (via email) and
40 invited to respond to additional questions about this event (e.g. medication brand name, dose and
41 timing, healthcare utilisation symptoms, other consequences). Non-response will not affect
42 participation in the study proper. De-identified information obtained about the event will be
43 submitted to the funder and, if relevant, the Australian Therapeutic Goods Administration.
44
45
46

47 Patient and public involvement

48
49 People with T2D were involved in the review and iterative refinement of the intervention content
50 and design. This involved cognitive debriefing interviews with six adults with T2D to review draft
51 content during intervention development, for which the findings and consequential refinements are
52 detailed elsewhere (33, 34). In addition, user ratings and qualitative feedback were provided by 13
53 pilot RCT participants who were allocated to the intervention (34). Refinements made to the
54 intervention following piloting included, for example, improving website navigation between barrier
55 webpages and the addition of 'print-friendly' downloadable PDF content (34). People with T2D were
56 not involved in the development of the study design, nor will they be involved in conduct of the
57 study or dissemination of the study findings.
58
59
60

Ethics and dissemination

This trial received ethical approval Deakin University Human Research Ethics Committee (Ref: 2020-073). This study will be conducted in compliance with this protocol (version: SA-2017-11697; V2.2e 16 June 2020), which is registered with the Australian New Zealand Clinical Trials Registry (ACTRN: 12621000191897, registered Feb 23 2021). Note, this protocol was submitted for registration prior to recruitment of the first participant (Dec 10, 2020), though approved retrospectively following enrolment of the first participant (Jan 11 2021) and prior to last participant enrolment. Any changes to the protocol will be communicated to the human research ethics committee, funder, and trial register. Protocol registration will be updated with any approved amendments to the protocol, and protocol departures will be documented in any reports or manuscripts resulting from this study.

Potential participants view the study plain language form online (Appendix 1) and must indicate consent (by ticking a box) prior to participating. Participants are free to withdraw from the study at any time, and for any reason, prior to completion of data collection.

The findings will be prepared for academic presentation at scientific meetings and in peer-reviewed journals. A lay summary of findings will be published on the research team's website and disseminated via e-newsletter. Study findings will also be reported to the funding body.

De-identified data may be made available, upon request, to the funding body.

Discussion

This randomised controlled trial will provide high quality evidence regarding the efficacy and acceptability of a novel, web-based resource: *'Is insulin right for me?'*. Using best-practice intervention development principles and evaluation guidance (33, 34), the intervention was designed to reduce salient psychological barriers to insulin, which are extremely common among people with T2D and associated with deleterious delay of insulin uptake (14, 44). To our knowledge, this study will be the first fully-powered randomised controlled trial conducted to test the impact of any intervention specifically designed to address salient psychological barriers to insulin among adults with T2D reporting some level of psychological insulin resistance.

The described study will provide evidence of the acceptability of this web-based resource among Australians with T2D who report some level of psychological insulin resistance, which may inform real-world implementation strategies and further refinements as required. A potential limitation of this trial is the self-selection bias of the sample recruited via an invitation from the NDSS, which may not be representative of those most in need (i.e. those with a high HbA1c yet not at all willing to commence insulin) as well as linguistically diverse communities. If the intervention is shown to be efficacious, further research will be warranted to investigate its impact on timely insulin uptake (and consequently on HbA1c), as well as the feasibility of implementation in primary care settings among adults with T2D for whom treatment intensification is clinically indicated.

References

1. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes care*. 2018;41(12):2669-701.

2. Gunton JE, Cheung NW, Davis TME, Zoungas S, Colagiuri S. A new blood glucose management algorithm for type 2 diabetes: A position statement of the Australian Diabetes Society. *The Medical Journal of Australia*. 2014;201(11):650-3.
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2015;38(1):140-9.
4. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. *Cardiovascular Diabetology*. 2015;14(1).
5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. *New England Journal of Medicine*. 2008;359(15):1577-89.
6. Khunti S, Davies MJ, Khunti K. Clinical inertia in the management of type 2 diabetes mellitus: A focused literature review. *British Journal of Diabetes & Vascular Disease*. 2015;15(2):65-9.
7. Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. *Therapeutic advances in endocrinology and metabolism*. 2019;10:2042018819844694.
8. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: A retrospective cohort study of more than 80,000 people. *Diabetes Care*. 2013;36(11):3411-7.
9. Furler J, O'Neal D, Speight J, Manski-Nankervis J-A, Gorelik A, Holmes-Truscott E, et al. Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. *bmj*. 2017;356:j783.
10. Manski-Nankervis J-A, Furler J, O'Neal D, Ginnivan L, Thuraisingam S, Blackberry I. Overcoming clinical inertia in insulin initiation in primary care for patients with type 2 diabetes: 24-month follow-up of the Stepping Up cluster randomised controlled trial. *Primary Care Diabetes*. 2017;11(5):474-81.
11. Zafar A, Stone M, Davies M, Khunti K. Acknowledging and allocating responsibility for clinical inertia in the management of Type 2 diabetes in primary care: a qualitative study. *Diabetic Medicine*. 2014.
12. Furler J, Spitzer O, Young D, Best J. Insulin in general practice: Barriers and enablers for timely initiation. *Australian Family Physician*. 2011;40(8):617-21.
13. Gabbay RA, Kendall D, Beebe C, Cuddeback J, Hobbs T, Khan ND, et al. Addressing therapeutic inertia in 2020 and beyond: a 3-year initiative of the American Diabetes Association. *Clinical Diabetes*. 2020;38(4):371-81.
14. Holmes-Truscott E, Furler J, Blackberry I, O'Neal DN, Speight J. Predictors of insulin uptake among adults with type 2 diabetes in the Stepping Up Study. *Diabetes Research and Clinical Practice*. 2017;133:204-10.
15. Wrzal PK, Bunko A, Myageri V, Kukaswadia A, Neish CS, Ivers NM. Strategies to overcome therapeutic inertia in type 2 diabetes mellitus: A scoping review. *Canadian Journal of Diabetes*. 2020.
16. Polonsky WH, Fisher L, Hessler D, Stuckey H, Snoek FJ, Tang T, et al. Identifying solutions to psychological insulin resistance: an international study. *Journal of Diabetes and its Complications*. 2019;33(4):307-14.
17. Or KY, Yip BH-K, Lau CH, Chen HH, Chan YW, Lee KP. Peer Education Group Intervention to Reduce Psychological Insulin Resistance: A Pilot Mixed-Method Study in a Chinese Population. *Diabetes Therapy*. 2018;9(1):113-24.
18. Kuo CR, Quan J, Kim S, Tang AHy, Heuerman DP, Murphy EJ. Group visits to encourage insulin initiation: targeting patient barriers. *Journal of Clinical Nursing*. 2017;26(11-12):1705-13.
19. Holmes-Truscott E, Blackberry I, O'Neal DN, Furler J, Speight J. Willingness to initiate insulin among adults with type 2 diabetes in Australian primary care: Results from the Stepping Up Study. *Diabetes Research and Clinical Practice*. 2016;114:126-35.

20. Upsher R, Allen-Taylor M, Reece I, Chamley M, Ismail K, Forbes A, et al. Experiences of Attending Group Education to Support Insulin Initiation in Type 2 Diabetes: A Qualitative Study. *Diabetes Therapy*. 2020;11(1):119-32.
21. Holmes-Truscott E, Browne JL, Speight J. The impact of insulin therapy and attitudes towards insulin intensification among adults with type 2 diabetes: A qualitative study. *Journal of Diabetes and its Complications*. 2016;30(6):1151-7.
22. Holmes-Truscott E, Skinner TC, Pouwer F, Speight J. Negative appraisals of insulin therapy are common among adults with Type 2 diabetes using insulin: Results from Diabetes MILES – Australia cross-sectional survey. *Diabetic Medicine*. 2015:n/a-n/a.
23. Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: A systematic review. *Diabetic Medicine*. 2013;30(5):512-24.
24. Holmes-Truscott E, Pouwer F, Speight J. Further investigation of the psychometric properties of the insulin treatment appraisal scale among insulin-using and non-insulin-using adults with type 2 diabetes: results from diabetes MILES-Australia. *Health and Quality of Life Outcomes*. 2014;12(1):87.
25. Brod M, Alolga SL, Meneghini L. Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities. *The Patient: Patient-Centered Outcomes Research*. 2014;7(4):437-50.
26. Patel N, Stone MA, Hadjiconstantinou M, Hiles S, Troughton J, Martin-Stacey L, et al. Using an interactive DVD about type 2 diabetes and insulin therapy in a UK South Asian community and in patient education and healthcare provider training. *Patient Education and Counseling*. 2015;98(9):1123-30.
27. Horigan G, Davies M, Findlay-White F, Chaney D, Coates V. Reasons why patients referred to diabetes education programmes choose not to attend: a systematic review. *Diabetic Medicine*. 2017;34(1):14-26.
28. Brewster S, Bartholomew J, Holt R, Price H. Non-attendance at diabetes outpatient appointments: a systematic review. *Diabetic Medicine*. 2020.
29. Lui C-W, Coll JR, Donald M, Dower J, Boyle FM. Health and social correlates of Internet use for diabetes information: findings from Australia's Living with Diabetes Study. *Australian journal of primary health*. 2015;21(3):327-33.
30. van Vugt M, de Wit M, Cleijne WH, Snoek FJ. Use of behavioral change techniques in web-based self-management programs for type 2 diabetes patients: systematic review. *Journal of medical Internet research*. 2013;15(12):e279.
31. Abraham C, Michie S. A taxonomy of behavior change techniques used in interventions. *Health psychology*. 2008;27(3):379.
32. Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W, et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. *Annals of behavioral medicine*. 2013;46(1):81-95.
33. Holloway EE, Speight J, Furler J, Hagger V, O'Neal D, Skinner T, et al. 'Is Insulin Right for Me?' Development of a theory-informed, web-based resource for reducing psychological barriers to insulin therapy among adults with type 2 diabetes. *Australasian Diabetes Congress*; 11-13 November; Online2020.
34. Holmes-Truscott E, Holloway EE, Furler J, Hagger V, O'Neal D, Skinner T, et al. Feasibility and acceptability of a web-based intervention to reduce psychological barriers to insulin therapy among adults with type 2 diabetes: a two-armed pilot randomised controlled trial of 'Is Insulin Right for Me?'. *Australasian Diabetes Congress*; 11-13 November; Online2020.
35. Australian Institute of Health and Welfare. *Diabetes prevalence in Australia: an assessment of national data sources*. . Canberra: AIHW; 2009.
36. Speight J, Browne JL, Holmes-Truscott E, Hendrieckx C, Pouwer F. *Diabetes MILES - Australia (Management and Impact for Long-term Empowerment and Success): methods and sample*

1
2
3 characteristics of a national survey of the psychological aspects of living with type 1 or type 2
4 diabetes in Australian adults. BMC Public Health. 2012;12.

5 37. Polonsky WH, Hajos TRS, Dain MP, Snoek FJ. Are patients with type 2 diabetes reluctant to
6 start insulin therapy? An examination of the scope and underpinnings of psychological insulin
7 resistance in a large, international population. Current Medical Research and Opinion.
8 2011;27(6):1169-74.

9 38. Snoek FJ, Skovlund SE, Pouwer F. Development and validation of the insulin treatment
10 appraisal scale (ITAS) in patients with type 2 diabetes. Health and Quality of Life Outcomes. 2007;5.

11 39. Fitzgerald JT, Funnell MM, Anderson RM, Nwankwo R, Stansfield RB, Piatt GA. Validation of
12 the revised brief Diabetes Knowledge Test (DKT2). The Diabetes Educator. 2016;42(2):178-87.

13 40. Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, et al. Assessing psychosocial
14 distress in diabetes development of the diabetes distress scale. Diabetes Care. 2005;28(3):626-31.

15 41. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire.
16 Journal of psychosomatic research. 2006;60(6):631-7.

17 42. Polonsky WH, Fisher L, Snoek F, Weinger K, Jelsovsky Z, Parkin CG, et al., editors. Evaluation
18 of the confidence in diabetes scale (CIDS-2) for patients with poorly controlled T2DM. American
19 Diabetes Association's 69th Scientific Sessions; 2009; New Orleans.

20 43. Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in
21 behaviour change and implementation research. Implementation science. 2012;7(1):37.

22 44. Odawara M, Ishii H, Tajima N, Iwamoto Y. Impact of patient attitudes and beliefs to insulin
23 therapy upon initiation, and their attitudinal changes after initiation: The DAWN Japan study.
24 Current Medical Research and Opinion. 2016;32(4):681-6.

25 26 27 28 29 30 31 Acknowledgments

32
33
34 We thank the participants with T2D who participated in intervention development and piloting
35 phases. We thank Victoria Yutronich (The Australian Centre for Behavioural Research in Diabetes,
36 Diabetes Victoria) for website design and technical support and Shaira Baptista (Deakin University
37 for research assistance.

38 39 Author contributions

40
41
42 EHT and JS conceived of the intervention and the described program of research. EHT and JS
43 developed the study protocol, with input from all authors. EH, JS, TS and EHT led the development of
44 the intervention, with contributions from JF, and VH. EHT was responsible for drafting the
45 manuscript. All authors contributed to and approved the final manuscript.

46 47 48 Funding Statement

49
50
51 This work was supported by an instigator-sponsored-study grant from Sanofi-Aventis Australia Pty
52 Ltd (Sanofi). Sanofi was not involved in the study design, and will not be involved in the collection,
53 analysis or interpretation of the study data, but was given the opportunity to view the manuscript
54 prior to submission. The decision to submit for publication was made independently by the authors.
55 Sanofi will be allowed access to all de-identified data from the study for research and audit
56 purposes, if requested. Costs associated with participation incentives, website development and
57 data management were funded (in full, or partially) by the Australian Centre for Behavioural
58 Research in Diabetes (ACBRD). In-kind support including project oversight was provided by the
59 Investigator team. JS is supported by the core funding to the ACBRD provided by the collaboration
60

1
2
3 between Diabetes Victoria and Deakin University. EHT was supported by the same plus a Deakin
4 University Deans Research Postdoctoral Fellowship (2018-2020).
5
6

7 Competing interests statement

9 EHT has undertaken research funded by an unrestricted educational grant from Abbott Diabetes
10 Care, AstraZeneca, and Sanofi; received speaker fees from Novo Nordisk and Roche to Australian
11 Centre for Behavioural Research in Diabetes (ACBRD); and served on an advisory board for
12 AstraZeneca. EEH has no conflicts of interest to disclose. JF has received unrestricted educational
13 grants for research support from Roche, Sanofi, and Medtronic. TS serves on advisory boards for
14 Novo Nordisk and Liva Health Care, and is currently on a EIT Health research grant held jointly with
15 Roche Diagnostics. JS has served on advisory boards for Janssen, Medtronic, Roche Diabetes Care,
16 and Sanofi Diabetes; her research group (Australian Centre for Behavioural Research in Diabetes
17 [ACBRD]) has received honoraria for this advisory board participation and has also received
18 unrestricted educational grants and in-kind support from Abbott Diabetes Care, AstraZeneca,
19 Medtronic, Roche Diabetes Care, and Sanofi Diabetes. JS has also received sponsorship to attend
20 educational meetings from Medtronic, Roche Diabetes Care, and Sanofi Diabetes, and consultancy
21 income or speaker fees from Abbott Diabetes Care, AstraZeneca, Medtronic, Novo Nordisk, Roche
22 Diabetes Care, and Sanofi Diabetes. All other authors have no conflicts of interest to declare.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix 1. Plain Language Statement and Consent Form

Attitudes towards insulin therapy for people with type 2 diabetes

Plain Language Statement and Consent Form

Date: May 2020

Full Project Title: Development, Feasibility, and Efficacy of a Web-Based Intervention to Reduce Psychological Barriers to Insulin Therapy among Adults with Type 2 Diabetes (Stage 3: Full RCT)

Principal Investigators: Dr Elizabeth Holmes-Truscott and Professor Jane Speight, The Australian Centre for Behavioural Research in Diabetes (ACBRD), Deakin University

Associate Investigators: Dr Edith Holloway, ACBRD, Deakin University; Professor Timothy Skinner, Department of Rural Health, La Trobe University; Associate Professor John Furler, Department of General Practice, The University of Melbourne; Professor David O'Neal, St Vincent's Hospital, The University of Melbourne; and Dr Virginia Hagger, School of Nursing and Midwifery, Deakin University.

Dear participant,

You are invited to take part in this research project because you have type 2 diabetes, are aged between 18 and 75 years of age and take oral medication to manage your diabetes. In this study, we are investigating people's attitudes towards injecting insulin. We are also testing online resources about medications for type 2 diabetes. We want to know which resource(s) is the most useful for people with type 2 diabetes, who have questions or concerns about injecting insulin. Taking part involves exploring the web-based resource(s) and completing three online surveys over 6 months.

Below you can read further information about the study, so that you can decide if you would like to take part. Please take the time to read this information carefully. You can also print a copy of the [PDF](#) (*hyperlink to ethics approved version of the PLS inserted here*) or ask the

1
2
3 study team for a hard copy to be sent to you. Ask the study team questions about anything
4 you don't understand or want to know more about.
5
6

7 If you consent to taking part in this study, please click the box at the end of this webpage.
8
9

10 **What is the purpose of this research?**

11
12 Insulin is very effective for lowering blood glucose levels. Your doctor may recommend
13 injecting insulin if other medications are unable to keep your blood glucose within your target
14 range. However, people with type 2 diabetes may have concerns or questions about starting
15 insulin. The purpose of this study is to test whether web-based resource(s) are useful for
16 people with type 2 diabetes who have questions or concerns about starting insulin injections.
17 The findings of this research may be used to inform what online resources about
18 medications are available for people with type 2 diabetes in the future. We expect a total of
19 392 adults with type 2 diabetes will take part in this study.
20
21
22
23
24
25
26
27
28
29
30

31 **Who can take part?**

32 You can take part in this study if you:
33

- 34 • have type 2 diabetes and are currently taking oral medication to manage your
35 diabetes. If you are currently, or have in the past, used self-administered injectable
36 treatment for any illness or condition (for example insulin) you are NOT eligible to
37 take part in the study.
- 38 • are between 18 and 75 years of age
- 39 • are able to read and speak English
- 40 • currently live in Australia
- 41 • have access to the internet and a computer (desktop, laptop) or tablet

42
43
44
45
46
47
48
49
50 You are not eligible to take part if you participated in the associated Pilot Study (between
51 October and December 2019): Development, Feasibility, and Efficacy of a Web-Based
52 Intervention to Reduce Psychological Barriers to Insulin Therapy among Adults with Type 2
53 Diabetes (Stage 2: Pilot Study).
54
55
56

57 **What does taking part involve?**

58
59
60

1
2
3
4 Taking part in this study will involve:
5

- 6 • Accessing and viewing a web-based resource(s) about medications for type 2 diabetes.
7 You will be asked to do this at least once (and as many times you like) over a 2-week
8 period.
9
- 10 • Completing three online surveys. The first survey will be upon entry to the study, the
11 second survey will be emailed to you two weeks later and the third survey will be emailed
12 to you at 6-months.
13
- 14 • Each survey will take 20 minutes to complete.
15
- 16 • The survey will include questions about you (age, gender, education), your diabetes,
17 attitudes and knowledge about insulin, your understanding about diabetes and some
18 questions about how diabetes makes you feel.
19
- 20 • You will also be asked to provide your name and email address. This is so we can link
21 each of your surveys together and look at any changes in your responses over time. Any
22 information you share with us will remain confidential.
23
24
25

26 After you have completed the first online survey on entry into the study, you will be allocated
27 to one of two groups. You will receive a link to one of two web-based resources on insulin
28 and type 2 diabetes. You have a 50% chance of being assigned to each group (like tossing
29 a coin). You will have two weeks to explore the resource(s) allocated to you. We will send
30 you an e-mail reminder during the two-week period to look at the resources. You will then be
31 sent follow-up surveys at 2 weeks and 6 months.
32
33
34
35
36

37 Taking part in this study does not involve any change to your diabetes management or
38 changes to the medications you take.
39
40

41 **Who is conducting this study?** 42

43 Deakin University is conducting this study with funding from Sanofi-aventis Australia Pty Ltd
44 (Sanofi). The study is coordinated by researchers (Principal Investigators) at The Australian
45 Centre for Behavioural Research in Diabetes (ACBRD), a partnership for better health
46 between Diabetes Victoria and Deakin University. The Principal Investigators take
47 responsibility for the study. Participants will only be contacted by the research team including
48 the principal investigators, the study project manager or research assistant.
49
50
51
52
53

54 **Are there any benefits for me personally?** 55

56 People take part in studies like this for many reasons. For example:
57

- 58 • Taking part offers an opportunity to learn about and inform new diabetes research;
59
60

- Taking part offers an opportunity to think about your diabetes and reflect on your experiences;
- Taking part in research will help us to help other people with diabetes (either now or in the future).

In addition, participants who complete the study (i.e., access the web-based resource(s) and complete all three surveys) will be entered into a prize draw to win one of 20 \$100 department store gift cards that can be used at over 20 major retail stores in Australia.

Are there any risks to me?

No, we do not believe that this study will cause you any harm or put you at risk of harm. The study surveys include questions that may be sensitive or personal in nature (e.g. feelings about living with diabetes, income and employment status). However, we do not expect any question to cause you any distress. If you should become upset during the survey, you may stop completing the questions at any time. We encourage you to contact the researchers to discuss this. The researchers will be understanding and supportive. You have the right to refuse to answer any question that makes you uncomfortable.

If, as a result of participation, you do become distressed, you may wish to seek further information and support from beyondblue: Beyondblue – National Information Line Ph: [REDACTED] or visit: <http://www.beyondblue.org.au/>

If you have any questions about your diabetes following the survey, we encourage you to contact your health professional or to call the National Diabetes Services Scheme Helpline: [REDACTED].

Can I withdraw at any time?

Yes. You are free to withdraw from this study at any time. If you decide not to take part while completing an online survey, you can stop the survey and notify a member of the research team. Deciding not to take part (or to withdraw) will not affect your relationship with the ACBRD, Deakin University, Diabetes Victoria, or the study funder (Sanofi). If you withdraw from the study before, during, or immediately after you have completed the online surveys, we can remove any information you have shared from our analysis. However, once the study is closed your data will be de-identified and merged with other people's data. This means that you will not be able to withdraw the information you shared because we will not know which data are yours.

What will happen to my information?

Any information you share with us will remain strictly confidential. The survey data will be stored in a database via the Deakin University secure network. Only the research team will have access to the password protected data. Once we have collected all of the data and are ready to analyse the results, the survey responses will be downloaded and de-identified. These files will not include any identifying information about you. Identifiable information (for example your email, name) will be stored in a password-encrypted excel spreadsheet. Any personal details you share about yourself (e.g. surname, contact details) for the purposes of enrolling you into the study will be destroyed (electronic files to be deleted) after you have completed the final survey. Safety follow-up interview data will be stored electronically (i.e. audio files). All data will be stored in a secure Deakin University computer file accessible only by the ACBRD research team. In accordance with government requirements, your data will be stored for at least fifteen (15) years following the publication of the results and then destroyed by erasing electronic files and shredding paper copies.

The overall results of the study may be published or presented in academic journals, at conferences, and in diabetes magazines and newsletters. Participants will be able to access any publications or reports resulting from the study on the ACBRD website (www.acbrd.org.au). No-one will be able to identify you from any of the information we publish or present. The study funder may request access to the de-identified data. These data will not include any information that could be used to identify you. We will take great care to protect your identity. Your privacy is very important to us.

Who is funding this project?

This project forms part of an Investigator Sponsored Study (SA-2017-11697) which is supported by Sanofi-aventis Australia Pty Ltd (Sanofi). Sanofi has no involvement in the study design, data analysis or interpretation and will not have any access to personally identifying information collected (e.g. contact details). De-identified study data may be shared with Sanofi, including survey results. Your personal and contact details will not be shared with Sanofi.

If you share with us (via the study surveys, e-mail or phone) any adverse events (safety issues) associated with therapeutic goods (e.g. medications) during your involvement with

1
2
3
4 this study, we are required to report these to Sanofi. This could include any adverse events
5 associated with the funder's products. Therefore, all the data that we collect from you will be
6 screened for adverse events that may be associated with medications you take now or have
7 taken in the past. In the event that you report an adverse event, we will contact you and ask
8 a small number of additional questions (e.g. medication brand, dose, symptoms etc). If you
9 decide not to answer the questions, this will not affect your participation in the study.
10
11
12

13
14 In addition, the researchers will notify the Deakin University Human Research Ethics Committee
15 (DUHREC) of any adverse incidents, events, reactions that have a possible causal relationship with
16 this research.
17

18 **Has this study been approved by an Ethics committee?**

19
20
21 Yes. This study has been reviewed and approved by Deakin University's Human Research Ethics
22 Committee (DUHREC), reference number 2020-073.
23

24 **Who can I contact about this study?**

25
26
27 If you would like further information or have any questions about the study, please contact:

28
29 Dr Elizabeth Holmes-Truscott (e: [REDACTED] t: [REDACTED]),

30
31 Professor Jane Speight (e: [REDACTED] t: [REDACTED]), or

32
33 Dr Edith Holloway (e: [REDACTED] t: [REDACTED]), at the ABCRD.

34
35 To find out more about the work of the ABCRD, you may like to visit the website:

36
37 www.acbrd.org.au.

38
39
40 If you have any complaints about any aspect of the project, the way it is being conducted or
41 any questions about your rights as a research participant, then you may contact:

42
43 The Human Research Ethics Office, Deakin University, 221 Burwood Highway, Burwood
44 Victoria 3125, Telephone: [REDACTED], email: [REDACTED]. Please quote project number
45 2020-073.
46
47
48
49
50
51
52

53 **Consent Form**

54
55
56
57
58 **Please tick the box at the bottom of the page to indicate your agreement with each**
59 **statement.**
60

- I have read and I understand the Plain Language Statement.
- I freely agree to participate in this project according to the conditions in the Plain Language Statement.
- I have access to a copy of the Plain Language Statement and Consent form to print and keep.
- I understand and consent to completing three online surveys: at entry into the study, two-weeks and 6-months later. I will also be invited to explore web-based resources about type 2 diabetes and injecting insulin.
- I understand that if I report any adverse events (safety issues) associated with therapeutic goods (e.g. medications) I will be contacted and asked a small number of additional questions. If I decide not to answer the questions, this will not affect my participation in the study.
- I understand that the research team will not reveal my identity or personal details to anyone outside the research team, including where information is published or presented in any public form about this research study.
- I understand that the research team or the study funders may use the information I share in a closely related project, or an extension of the current research project, and that this information will be de-identified.

I have read and understood the information above and agree to take part in this study.

I am ready to start completing the Attitudes Towards Insulin Study

Withdrawal Form

To be used for participants who wish to withdraw from the project

Date: May 2020

Full Project Title: Development, Feasibility, and Efficacy of a Web-Based Intervention to Reduce Psychological Barriers to Insulin Therapy among Adults with Type 2 Diabetes (Stage 3: Full RCT)

Reference Number: 2020-073

*******IMPORTANT*******

Complete this form and return it to us only if you decide to WITHDRAW from the above-named study.

I wish to withdraw from participating in the study entitled 'Development, Feasibility, and Efficacy of a Web-Based Intervention to Reduce Psychological Barriers to Insulin Therapy among Adults with Type 2 Diabetes (Stage 3: Full RCT)'. I do not want to take part in any additional study activities *and* I do not want the information I have already provided to be included in any analysis or study publications. I understand that withdrawing the information I have already provided will not be possible after completion of the second survey. I understand that withdrawing from the study will not adversely affect my relationship with any of the organisations conducting this study. I understand that withdrawing from the study will not affect the care or treatment I receive from any health professionals.

Participant's name (please print)

.....

Participant's signature.....

Date.....

Dr Elizabeth Holmes-Truscott

The Australian Centre of Behavioural Research in Diabetes

570 Elizabeth St, Melbourne, VIC 3000

T: [REDACTED]

E: [REDACTED]

For peer review only



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ItemNo	Description	Author response
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Title: A web-based intervention to reduce psychological barriers to insulin therapy among adults with non-insulin-treated type 2 diabetes: study protocol for a two-armed randomised controlled trial of 'Is Insulin Right for Me?
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	ACTRN1262100091897
	2b	All items from the World Health Organization Trial Registration Data Set	See trial registration details.
Protocol version	3	Date and version identifier	Protocol number, version, date: SA-2017-11697; V2.2e 16 June 2020 (See title page & main text: 'Ethics and dissemination')
Funding	4	Sources and types of financial, material, and other support	See <i>Funding statement</i> .
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	See <i>Authorship contribution statement</i>
	5b	Name and contact information for the trial sponsor	See <i>Funding statement</i>

bmjopen-2021-051524 on 21 February 2024. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	See <i>Funding statement</i>
18	Introduction		
19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
		6b	Explanation for choice of comparators
	Objectives	7	Specific objectives or hypotheses
	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
	See <i>Introduction</i> , from paragraph 3		
	See <i>Introduction</i> , paragraph 4, and final paragraph.		
	See <i>Introduction</i> , final paragraph.		
	See <i>Introduction</i> , final paragraph.		
	See <i>Funding statement</i> ; <i>Authorship contribution statement</i> , and; main text (<i>Monitoring</i>)		

Methods: Participants, interventions, and outcomes

1				
2				
3				
4	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	See <i>Methods and analysis, Study setting</i>
5				
6				
7				
8				
9	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	See <i>Methods and analysis, Participants and recruitment</i>
10				
11				
12				
13				
14				
15	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	See <i>Methods and analysis, Intervention</i> See <i>Methods and analysis, Control group</i>
16				
17				
18				
19				
20		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	N/A
21				
22				
23				
24				
25				
26		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	See <i>Methods and analysis, Data collection, management and analysis</i> , second paragraph. See <i>Methods and analysis, Outcomes</i> , final paragraph.
27				
28				
29				
30		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1				
2				
3				
4	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	See <i>Methods and Analysis, Outcomes</i>
5				
6				
7				
8				
9				
10				
11				
12				
13	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	See <i>Methods and Analysis, Study procedure, Figure 1.</i>
14				
15				
16				
17				
18				
19	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	See <i>Methods and Analysis, Sample size</i>
20				
21				
22				
23				
24	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	See <i>Methods and Analysis, participants and recruitment</i>
25				
26				
27				
28	Methods: Assignment of interventions (for controlled trials)			
29	Allocation:			
30				
31	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	See <i>Methods and Analysis, Randomisation and blinding</i>
32				
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	See <i>Methods and analysis, Randomisation and blinding</i>
Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	See <i>Methods and analysis, Randomisation and blinding</i>
Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	See <i>Methods and analysis, Randomisation and blinding</i>
	17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	See <i>Methods and analysis, Randomisation and blinding</i>
Methods: Data collection, management, and analysis			
Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	See <i>Methods and analysis, Outcomes</i> See <i>Methods and analysis, Study procedure, Figure 1.</i>
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	See <i>Methods and analysis, Data collection, management and analysis, second paragraph.</i>

1				
2				
3				
4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	See <i>Methods and analysis, Data collection, management and analysis, Data storage..</i>
5				
6				
7				
8				
9				
10	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	See <i>Methods and analysis, Data collection, management and analysis, Statistical methods</i>
11				
12				
13				
14				
15		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	See <i>Methods and analysis, Data collection, management and analysis, Statistical methods</i>
16				
17				
18		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	See <i>Methods and analysis, Data collection, management and analysis, Statistical methods</i>
19				
20				
21				
22				
23				
24	Methods: Monitoring			
25				
26	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	See <i>Methods and analysis, Data collection, management and analysis, Monitoring.</i>
27				
28				
29				
30				
31				
32				
33				
34		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1				
2				
3				
4	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	See <i>Methods and Analysis, Monitoring</i> .
5				
6				
7				
8				
9	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	N/A The primary funding body will be allowed access to all de-identified data from the study for audit purposes, if requested.
10				
11				
12				
13				
14				
15	Ethics and dissemination			
16				
17	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	See <i>Ethics and dissemination</i> : This trial received ethical approval Deakin University Human Research Ethics Committee (Ref: 2020-073).
18				
19				
20				
21				
22	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	See <i>Ethics and dissemination</i> .
23				
24				
25				
26				
27	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	See <i>Ethics and dissemination</i> .
28				
29				
30				
31				
32		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	See <i>Methods and analysis, Data collection, management and analysis</i>
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	See <i>Competing interests statement</i>
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	See <i>Methods and analysis, Data collection, management and analysis, Data Storage.</i> See <i>Ethics and dissemination</i> : De-identified data may be made available, upon request, to the funding body.
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	See <i>Ethics and dissemination.</i>
	31b	Authorship eligibility guidelines and any intended use of professional writers	See <i>Authorship contribution statement.</i>
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A

Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Appendix 1.
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.

BMJ Open

A web-based intervention to reduce psychological barriers to insulin therapy among adults with non-insulin-treated type 2 diabetes: study protocol for a two-armed randomised controlled trial of 'Is Insulin Right for Me?'

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-051524.R1
Article Type:	Protocol
Date Submitted by the Author:	02-Dec-2021
Complete List of Authors:	Holmes-Truscott, Elizabeth; Deakin University, School of Psychology; Diabetes Victoria, The Australian Centre for Behavioural Research in Diabetes Holloway, Edith; Deakin University, School of Psychology; Diabetes Victoria, The Australian Centre for Behavioural Research in Diabetes Husin, Hanafi; Deakin University, School of Psychology; Diabetes Victoria, The Australian Centre for Behavioural Research in Diabetes Furler, John; University of Melbourne, Department of General Practice Hagger, Virginia; Deakin University, School of Nursing and Midwifery Skinner, Timothy; La Trobe University, Rural Health School; University of Copenhagen, Department of Psychology Speight, Jane; Deakin University, School of Psychology; Diabetes Victoria, The Australian Centre for Behavioural Research in Diabetes
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Patient-centred medicine
Keywords:	DIABETES & ENDOCRINOLOGY, Clinical trials < THERAPEUTICS, SOCIAL MEDICINE

SCHOLARONE™
Manuscripts

1
2
3 **Target journal:** BMJ open
4

5 **Article type:** Research article - Clinical
6

7 **Title:** A web-based intervention to reduce psychological barriers to insulin therapy among adults
8 with non-insulin-treated type 2 diabetes: study protocol for a two-armed randomised controlled trial
9 of '*Is Insulin Right for Me?*'
10

11 **Running title:** Reducing barriers to insulin: randomised control trial protocol
12

13 **Protocol number, version, date:** SA-2017-11697; V2.2e 16 June 2020
14

15 **Authors:**
16

17 Dr Elizabeth Holmes-Truscott^{1,2}, Dr Edith E Holloway^{1,2}, Mr Hanafi M Husin^{1,2}, Associate Prof John
18 Furler³, Dr Virginia Hagger⁴, Prof Timothy Skinner^{2,5,6} and Prof Jane Speight^{1,2},
19

20 **Affiliations:**
21

- 22 1. School of Psychology, Deakin University, Geelong, Victoria, Australia
- 23 2. The Australian Centre for Behavioural Research in Diabetes, Diabetes
24 Victoria, Melbourne, Victoria, Australia
- 25 3. Department of General Practice, The University of Melbourne, Carlton, Victoria, Australia
- 26 4. School of Nursing and Midwifery, Deakin University, Burwood, Victoria, Australia
- 27 5. La Trobe Rural Health School, La Trobe University, Victoria, Australia
- 28 6. Department of Psychology, University of Copenhagen, Copenhagen, Denmark
- 29
- 30
- 31
- 32
- 33
- 34

35 **Corresponding author:**
36

37 Dr Elizabeth Holmes-Truscott
38 etruscott@acbrd.org.au
39 570 Elizabeth Street Melbourne 3000 Vic Australia
40
41

42 Total word count: 4126 (max:4000)

43 Table/figures: 2

44 Abstract: 250 (max 250)

45 References:
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Psychological barriers to insulin therapy are associated with the delay of clinically indicated treatment intensification for people with type 2 diabetes (T2D), yet few evidence-based interventions exist to address these barriers. We describe the protocol for a randomised controlled trial (RCT) examining the efficacy of a novel, theoretically-grounded, psycho-educational, web-based resource designed to reduce psychological barriers to insulin among adults with non-insulin treated T2D: *"Is insulin right for me?"*.

Methods and analysis: Double-blind, parallel group RCT. A target sample of N=392 participants (n=196/arm) will be randomised (1:1) to *"Is insulin right for me?"* (intervention) or widely available online resources (control). Eligible participants include adults (18-75 years), residing in Australia, currently taking oral hypoglycaemic agents to manage T2D. They will be primarily recruited via invitations and reminders from the national diabetes registry (from a purposefully selected sample of N≥12,000). Exclusion criteria: experience of self-administered injectable; previously enrolled in pilot RCT; "very willing" to start insulin as baseline. Outcomes will be assessed via online survey at two weeks and six months. Primary outcome Between-group: difference in mean negative insulin treatment appraisal scores (ITAS Negative) at two-week and six-month follow-up. Secondary outcomes: Between-group differences in mean positive insulin appraisals (ITAS Positive) and percentage difference in intention to commence insulin at follow-up time-points. All data analyses will be conducted according to the intention-to-treat principle.

Ethics and dissemination: Deakin University Human Research Ethics Committee (2020-073). Dissemination via peer-reviewed journals, conferences and a plain-language summary.

Trial registration: Australian and New Zealand Clinical Trials Registry ACTRN12621000191897

Strengths and limitations of this study

- *'Is insulin right for me?'* is the first self-directed, theoretically-grounded web-based intervention targeting salient psychological barriers to insulin.
- This fully-powered randomised controlled trial will provide evidence of the impact of *'Is insulin right for me?'* to reduce negative insulin appraisals and increase intention to initiate insulin among adults with non-insulin-treated type 2 diabetes (T2D) recruited via a national diabetes registry.
- Comprehensive data collection, including demographic and clinical characteristics, psychosocial outcomes, and website analytics, will enable process evaluation analyses.
- Limitations include the self-selected sample, which may lead to an under-representation of those hardest to reach or most at need (i.e. those not at all willing to commence insulin).
- Further, this study is not designed to identify the intervention's impact on actual timely insulin uptake nor feasibility of implementation within clinical care.

Introduction

Type 2 diabetes (T2D) is a progressive condition that requires timely adjustment of treatment to achieve and maintain optimal glucose outcomes (1-3), and prevent or delay the onset of micro and macrovascular complications (4, 5). A staged approach to pharmacological management of glucose in T2D is recommended (1-3), including early consideration and initiation of insulin where glycaemic outcomes are above target (typically HbA1c >7%, 53 mmol/mol (2)) despite maximal dose of non-insulin medicines. However, vast literature suggests that treatment adjustment, including insulin initiation, is often delayed well beyond the point of clinical need (6, 7). For example, a large-scale (N=>80,000), retrospective study conducted in the UK, identified HbA1c at insulin initiation for people with T2D was ≥8.7% (72 mmol/mol) with a median time until insulin initiation of ≥6 years (8). Finally, a recent Australian primary care based prospective study identified that, among adults with T2D for whom insulin was clinically indicated (HbA1c ≥7.5%/58mmol/mol, with maximal oral therapy), receiving usual care, only 31% had initiated insulin within 24 months (9, 10).

Reasons for the delay of treatment intensification are multifaceted (7, 11, 12), and effective interventions targeting barriers to insulin use are required (13-15). At a systemic or health professional level, promising results have been shown using multi-disciplinary models of care (e.g. an enhanced practice nurse role within primary care setting (9)), effective consultation strategies (e.g. collaborative approach to care (16)), and insulin-specific structured education programs (17, 18). However, there is a parallel need for interventions which directly target the psychological barriers (negative beliefs and attitudes) to insulin held by the person with T2D. Our prior research demonstrated, independent of an optimised model of primary care ('stepping up'), attitudes toward insulin were associated with hypothetical willingness to initiate insulin, which, in turn predicted actual insulin use 12 months later (14, 19). Elsewhere, qualitative research with people with T2D attending an insulin-specific education program identified an unmet need for psychological barriers to insulin to be addressed appropriately (20). Furthermore, unaddressed negative insulin appraisals may have long-lasting impact on the optimal use of insulin and/or emotional wellbeing following insulin initiation (21-23). Such psychological barriers to insulin use include, for example, worries about performing injections, potential pain and side effects, as well as feelings of guilt and self-blame about the onset of the condition and/or the need for treatment progression (24).

Few evidence-based interventions targeting psychological barriers to insulin have been developed and fewer still are evaluated adequately, or implemented beyond research studies (17, 25, 26). Furthermore, preliminary data from relevant clinic-based and insulin starts group-education interventions suggest low intervention uptake among people with T2D (17, 26). In addition to common barriers to outpatient clinic and structured education program attendance discussed elsewhere (27, 28), this low uptake may be in part due to individuals concern that participation would lead to insulin acceptance (26). Furthermore, health professionals report limited time and resources to facilitate insulin starts (12), and express concerns about the added burden of intervention delivery on their already limited time (26). Effective interventions that complement clinical care (but are not reliant on a health professional for delivery) have the potential to be acceptable to both people with T2D and their health professionals.

Given the sheer size of the population with T2D, the potential for scalable implementation is also an important consideration. The internet may be an ideal platform to reach those with T2D with concerns about insulin, as it also allows for anonymity in information seeking. One third of Australian adults with T2D and suboptimal HbA1c report seeking online health information in a past 12 period (29). Further, online interventions for the management of T2D with clear theoretical groundings and

1
2
3 based on behaviour change techniques show favourable outcomes (30). While peak health bodies
4 publish resources online about T2D treatments, these materials are not typically theoretically
5 informed, do not use evidence-based behaviour change techniques (31, 32), and are rarely
6 developed in consultation with, or evaluated among, people with T2D. Further, these resources are
7 rarely targeted at addressing salient psychological barriers to treatment use.
8

9
10 In line with UK Medical Research Council (MRC) guidance for developing and evaluating complex
11 intervention, we developed a theoretically-grounded, psycho-educational, web-based resource for
12 people with non-insulin-treated T2D designed to reduce salient psychological barriers to insulin
13 therapy: '*Is insulin right for me?*' (33). A pilot study demonstrated feasibility of a two-arm
14 randomised controlled trial (RCT) design to test intervention efficacy, compared with widely
15 available online informational resources, as well as acceptability of the intervention among adults
16 with T2D (34).
17

18 This protocol describes the design of a double-blinded, parallel group, individually randomised
19 controlled trial (two-arms, 1:1 ratio), comparing '*Is insulin right for me?*' (intervention) with widely
20 available online text-based resources about insulin (control) among adults with non-insulin-treated
21 T2D. We hypothesise an immediate (two weeks) and sustained (six months) positive effect of the
22 intervention, compared to control, on negative insulin appraisals. We also expect the intervention to
23 be acceptable to users and to be associated with immediate and sustained improvement in positive
24 insulin appraisals and hypothetical willingness to begin insulin therapy.
25

26 27 28 Methods and analysis

29 30 Study setting

31 Participation in this Australian study, including provision of informed content, data collection and
32 intervention exposure, is completely online, using personal computers/mobile devices.
33

34 35 Participants and recruitment

36 Potential participants will be enrolled in the study only if they meet all the inclusion criteria and
37 none of the exclusion criteria. Inclusion criteria: aged 18 to 75 years; diagnosed with T2D; use of oral
38 hypoglycaemic agents (OHAs); able to read/write in English and capable of providing informed
39 consent; residing in Australia; access to an internet-enabled computer or tablet device for the
40 duration of the study. Exclusion criteria: diagnoses of diabetes other than T2D; current or prior
41 experience of self-administered injectable treatment for any illness or condition (including diabetes);
42 unable to read/write in English; unable to use/access internet-enabled devices; enrolled as a
43 participant in the pilot RCT (34); reports being "very willing" to initiate insulin therapy (measured
44 using a single-item "hypothetical willingness" questionnaire (35)), i.e. rendering it impossible to
45 record improvement in this outcome measure.
46

47
48 The primary method of recruitment will be via invitation from the National Diabetes Services
49 Scheme (NDSS). A random sample of $\geq 12,000$ NDSS registrants, aged 18-75 years with non-insulin-
50 treated T2D, who have previously consented to being contacted about research opportunities will be
51 invited to take part either via email ($n=10,000$) or postal mail ($n=2,000$) as per the registrants
52 preferred method of contact. The NDSS is an Australian government initiative, administered by
53 Diabetes Australia. The NDSS registry includes over 1.2 million Australians with T2D, and is
54 considered to be one of the most comprehensive and up-to-date diabetes prevalence datasets in
55 Australian (36). The random sample will be stratified by state and territory to facilitate
56 representation across Australia, ideally in line with population distribution across the eight states
57 and territories. The research team will not have access to NDSS registrants' details unless they make
58 contact/take part in the study, and the NDSS will not be notified of participating registrants. The
59 total number of invited registrants was selected based on adoption of a conservative response rate
60

1
2
3 of 8% (37), and an expected 46% translation from consent to enrolled participant (as seen in the
4 pilot RCT; (34)). Invited NDSS registrants will receive an invitation reminder via e-mail or postal mail
5 two weeks following first contact. If our target sample size is not reached within four weeks of the
6 initial invitation, a second NDSS e-mail/mailout will be sent until our target sample size is reached or
7 the two-month recruitment period has concluded. The number of registrants contacted and method
8 (e-mail vs. mail) for subsequent recruitment efforts will be informed by the success rate from the
9 original invitation (i.e. percentage enrolled reporting hearing about the study via email or mail
10 invitation). The study will also be advertised online via the researchers' affiliated professional
11 websites and social media accounts, and a study flyer will be circulated to diabetes researcher and
12 health professional networks.
13
14

15 Study procedure

16
17 The schedule of enrolment, intervention and assessment is detailed in Figure 1. Study recruitment
18 will be open for a maximum of two months or until sample size (enrolled) is reached. Participation
19 (from study entry to exit) will be for a duration of six months. Study advertisements will direct
20 potential participants to the study website (hosted by Qualtrics™) to access the Plain Language
21 Statement, provide informed consent, and complete screening questions online. Eligibility will be
22 determined automatically based on responses. Eligible participants will be directed immediately to
23 complete an online baseline survey, and, following submission, will be allocated at random to one of
24 two study arms. Randomised participants will receive an email including details about how to access
25 the relevant online resources for their study arm. For participants allocated to the intervention
26 group, this will include a unique username and password enabling access. All participants will be
27 asked to access their allocated resource(s) at their convenience within the following two-week
28 period, with no further instruction provided regarding the number of resource visits, or length of
29 time viewing the resources(s). One week following allocation, participants will receive a reminder
30 email to access/log into the resource. Participants will be sent an email with a link to the online
31 follow-up survey at two weeks and six months following baseline. The two-week follow-up survey
32 will be available for completion for two weeks, and the six-month follow-up survey will be available
33 for completion for three weeks. Study end-point for all participants will be marked by either
34 submission of the six-month follow-up survey (within 21 days of request), or non-submission at 22
35 days following the survey request.
36
37
38
39
40

41 Randomisation and blinding

42
43 After baseline survey submission, participants will be stratified by gender (due to prior gender
44 imbalance observed among participants recruited to related studies (9, 21)) and randomised to
45 either the intervention or control arm using computer-generated, randomly permuted block sizes of
46 four, six or eight. The randomisation sequence will be computer generated and the allocation will be
47 fully concealed from both the investigators and participants. Upon randomisation, participants will
48 receive an email from a researcher, independent of the study investigator team and who does not
49 have access to the incoming survey data (except for participant ID, name, gender and email address),
50 specifying access details to their allocated online resource. The statistician, participants, and
51 investigator team will remain blinded to study arm allocation throughout data collection and
52 analyses. The project manager (EEH), who will monitor incoming survey data, will be blinded from
53 study arm allocation except where a participant self-identifies study arm allocation within the follow
54 up surveys (e.g. in a free-text response box). Any breaches will be recorded and reported with the
55 main findings.
56
57
58
59
60

Intervention

Intervention group participants will receive access to a novel psycho-educational web-based resource, *'Is insulin right for me?'*. The intervention was developed using a systematic process grounded in behaviour change theory and has been described elsewhere (33). In brief, eight salient psychological barriers to insulin therapy were identified via literature search. Each barrier (i.e., determinant of behaviour) was mapped to relevant domains of the Theoretical Domains Framework (TDF) (38). Determinants were then mapped onto behaviour change techniques (BCTs) considered relevant to overcoming the modifiable barriers (32, 38). Content responding to each barrier was developed by the investigator team (experts in health psychology, primary care medicine and diabetes education) and refined following consumer feedback (cognitive debriefing interviews, n=6) and external expert peer review (n=5) to ensure relevance for people with T2D and clinical accuracy.

The eight barriers targeted in the *'Is insulin right for me'* resource are phrased as common questions, with one barrier/question per website page (See Table 1). The resource home page lists all eight barriers/questions as well as a preview (a key summary statement that responds to the question and content overview). The intervention is purposefully brief and self-directed, with the home page text asking which of eight questions about insulin are concerns for participants. For each selected barrier, an active intervention is presented on a separate webpage (200-500 words; 5-minute read) to facilitate user engagement. In addition, the resource includes information about the key benefits of insulin therapy: (1) that it lowers blood glucose levels; (2) can lower your risk of long-term health complications; (3) can make you feel better; and (4) can make managing your diabetes more flexible. The lesser focus on benefits than barriers is due to the evidence that most people with T2D experience / report barriers to insulin therapy despite endorsing benefits (14, 19). Finally, the resource also provides links to other resources about T2D and insulin available from the NDSS, and study information.

Table 1. Description of the eight barriers targeted in the *'Is insulin right for me'* resource

Barrier (Question)	Resource aim (using behaviour change theory)	Format of delivery
Does insulin mean my diabetes is more serious?	<ul style="list-style-type: none"> Challenge beliefs: Insulin therapy can be clinically recommended at any time Shape knowledge: Provide information about the role of insulin Motivate: Diabetes is always serious 	Interactive quiz; video depicting progressive nature of T2D (imagery and text), imagery and personal quote
Do insulin injections cause complications?	<ul style="list-style-type: none"> Shape knowledge: Provide information about diabetes complications risk factors Motivate: Acknowledge where this belief comes from. Validate concerns 	Text; imagery and personal quote
Is it my fault I need to inject insulin?	<ul style="list-style-type: none"> Identification of self as role model: 'You are doing this for yourself, insulin is a good thing' Restructuring the social environment: being prepared for how others may react Encouragement and support: Sharing how you feel with others 	Text; case study (with audio recording); statistic; and personal quote

1 2 3 4 5 6 7 8 9 10 11 12	Will I gain weight?	<ul style="list-style-type: none"> • Shaping knowledge: Many people gain a small amount of weight when they commence insulin therapy. There are things that you can do to prevent unhealthy weight gain • Motivate: Acknowledge and validate fear • Salience of side effect: for many, weight gain is small 	Interactive quiz; text; imagery and personal quote
13 14 15 16 17 18 19 20 21 22 23	Will injecting hurt?	<ul style="list-style-type: none"> • Shaping beliefs: Dispel myths • Manage expectations: Information and strategies to alleviate and minimise discomfort • Demonstration: of a person injecting insulin • Encouragement: to discuss insulin therapy and any concerns with a health professional • Imagery: small/fine needles & site of the injection 	Text; demonstration of injecting insulin; imagery and personal quote
24 25 26 27 28 29 30	What about hypos?	<ul style="list-style-type: none"> • Shape knowledge: Frequency/severity of hypos • Motivate: Acknowledge/validate fears 'having concerns about hypos is natural'. • Reduce emotional valence of the fear: Low risk of having a severe hypo. Support is available 	Interactive quiz; text; imagery and personal quote
31 32 33 34 35 36 37 38	Will injecting insulin be a burden?	<ul style="list-style-type: none"> • Increase knowledge: You can take insulin with you wherever you go • Increase self-efficacy: The changes you need to make are minimal and you can handle them. • Weigh pros versus cons: Insulin can make management of diabetes easier 	Text and personal quote
39 40 41 42 43 44 45 46 47 48	What will others think of me?	<ul style="list-style-type: none"> • Identification of self as role model: 'You are doing this for yourself, insulin is a good thing' • Restructuring the social environment: being prepared for how others may react • Encouragement and support: Start a 'safe' conversation to share how you feel with others 	Case studies with examples (with audio recording); text; and personal quote

Control group

Control arm participants will be directed to a static webpage including links to publicly available text-based NDSS factsheets, including: "Insulin" and "Medication for type 2 diabetes". The control group webpage also includes links to further information about the study and research team (consistent with intervention arm).

Outcomes

The co-primary outcome measures are the difference in mean negative insulin appraisals, as measured by the Insulin Treatment Appraisal Scale (ITAS) Negative subscale score (39), between the intervention and control arm at two-week and six-month follow-up, adjusted by baseline scores. We hypothesise that, at two weeks, a statistically significant difference in mean ITAS Negative scores of ≥ 4 points (approximately 0.5 standard deviations) will be observed between the intervention and control arm, favouring the intervention arm; and that this difference will be sustained at six months.

Our secondary outcome measures are immediate and sustained between-arm differences in: a) positive insulin appraisals, as measured by ITAS Positive subscale score (39); and b) hypothetical willingness to begin insulin therapy, as measured by a single item (35). We hypothesise that, at two weeks and six months, a statistically significant between-group difference will be observed in:

1. mean ITAS Positive scores, adjusted for baseline scores, favouring the intervention arm;
2. the percentage of participants who respond 'not at all willing' (hypothetical willingness item). The intervention arm will be less likely to be 'not at all willing' compared to controls.

The following survey data will be examined by study arm for process evaluation purposes:

1. Clinical discussion and recommendation of insulin therapy, change in medications, and satisfaction with diabetes management at six-month follow up
2. Change in secondary psychosocial outcome scores at two-week and six-month follow up: diabetes-specific distress (PAID) (40), illness perceptions (BIPQ) (41), diabetes-specific self-efficacy (CIDS) (42), study-specific insulin-related knowledge questionnaire.
3. Diabetes-specific knowledge at baseline (DKT) (43).
4. Study-specific resource use and acceptability (study specific items) as two-week follow up.

Figure 1 details the self-reported demographic, clinical, psychosocial, and study-specific data to be collected and the time-points at which they are to be collected. In addition, website analytics data will be collected to assess protocol fulfilment with the intervention resource (i.e. proportion of 'enrolled' participants who accessed the *'Is insulin right for me?'* website at least once). Various analytics (e.g. average number of online resource visits; time (minutes) spent on online resource; most commonly (frequency, %) viewed pages) will be examined to explore any relationship(s) between type/duration of content accessed and the study outcomes. Finally, number of views and average time spent watching two videos embedded in the intervention resource will be captured via YouTube.

Sample size

Using a power analysis for repeated measures analysis of variance, a minimum sample size of $N=250$ ($n=125$ per arm) is required to detect a minimally important difference of half a standard deviation ($SD=9$) in ITAS Negative Scores (39) between study arms with a correlation of 0.65 between repeated measures, at 85% power and 0.05 significance level using a two-sided test. Assuming a 20% attrition rate at two weeks (34) and a further 20% attrition at six months, the targeted sample size inflates to approximately $N=392$ ($n=196$ per arm). Overall, a 40% attrition rate is incorporated into our estimated sample size and replacements will not be made for losses to follow-up.

Data collection, management and analysis

Participant-reported data will be collected online via Qualtrics™, hosted through the Deakin University secure network. Consent, eligibility screening and baseline survey data will be collected in a single sitting (directed via study advertisement link), and an email will provide enrolled participants with a link to online follow-up surveys. The intervention website will require participant log-in,

1
2
3 allowing for automatic collection of website usage data for each intervention participant via Google
4 Analytics.
5

6 To improve participant retention and protocol compliance, trial participants will receive reminder
7 emails to access/view the allocated online resource (sent to all participants two weeks following
8 allocation. In addition, reminder emails will be sent at one week (and two weeks for six-month time-
9 point) to participants who have yet to commence their online follow-up surveys. To aid recruitment
10 and retention, participants who complete all three surveys (the baseline, two-week *and* six-month
11 follow-up) will be entered into a prize draw to win one of 20 \$100 e-gift vouchers.
12
13

14 Participants who do not access their allocated resource(s) will still be followed up until the end of
15 the trial unless they withdraw from the trial. Participants who do not complete the two-week follow
16 up survey will have 'missing data' at two weeks, but remain eligible to complete the six-month
17 follow up survey. Participants who do not complete the six-month follow up survey within three
18 weeks of receipt will have 'missing data' at six months. Participants with missing data at both follow-
19 up time-points will be deemed 'lost to follow-up'.
20
21

22 Study data collected from withdrawn participants will be deleted, with the exception of basic de-
23 identified sample characteristics (gender, age, diabetes duration), trial arm allocation, timing of
24 withdrawal, and reason for withdrawal, where applicable.
25

26 Data storage

27
28 At study conclusion, survey data and website usage data (for intervention participants only) will be
29 downloaded from Qualtrics and Google Analytics, respectively, and linked according to participant
30 ID. Identifiable information (email, name) will be separated from study data and stored along with
31 participant ID number in a password-encrypted excel spreadsheet. All data will be stored in a secure
32 electronic file accessible only by the research team. In accordance with clinical trial regulations, data
33 will be kept for a minimum of 15 years after study completion and then disposed by erasing of
34 electronic files.
35
36

37 Statistical methods

38
39 Quantitative data analyses will be performed using Stata/SE 16.0 and/or IBM SPSS 26. Descriptive
40 statistics will be used to describe participant baseline characteristics and psychological outcomes at
41 each time point. Participant characteristics at baseline will be visually assessed by allocation for
42 imbalance. The overall characteristics of the study cohort will be compared to those lost to follow-
43 up.
44
45

46 An intention-to-treat (ITT) approach will be adopted whereby participants will be analysed according
47 to the arm they were allocated to, and all participants will be included in the analysis. A linear mixed
48 effects model will be used to estimate the difference in mean ITAS Negative scores between arms at
49 two weeks and six months using restricted maximum likelihood estimation. Treatment arm, all three
50 time-points (baseline, two weeks and six months), and the interaction between treatment arm and
51 time-points will be included as fixed effects in the model. Random effects will be used to account
52 for repeated participant measures. The outcome measure will be adjusted by age, diabetes duration
53 and education should these be imbalanced between the arms at baseline. As a sensitivity analysis,
54 pattern mixture models will be used to determine whether study conclusions from the analyses
55 described above would change should data be missing not at random.
56
57

58 ITAS Positive Scores (secondary outcome), and continuous psychosocial process evaluation
59 outcomes (e.g. PAID, BIPQ, CIDS) will be analysed using the same modelling approached described
60

1
2
3 above. An ordinal logistic mixed effects model will be used to quantify between-arm differences in
4 the willingness to begin insulin therapy (secondary outcome) at the various time points.
5

6 Descriptive data will be used to explore trends in protocol fulfilment, website analytics and
7 acceptability data, as well as medication changes and clinical discussion of insulin therapy at six
8 months separately for each study arm.
9

10 11 Monitoring

12 Co-authors EHT and JS are the responsible investigators and will oversee the research project.
13 During recruitment and data collection, the number of potential participants consenting, eligible and
14 enrolled as well as dates of all participant encounters (i.e. enrolment; intervention access &
15 reminder emails; survey access, reminder and closure) and survey completion will be monitored by
16 EEH and communicated to investigator team. The primary funding body will be allowed access to all
17 de-identified data from the study for audit purposes, if requested.
18
19

20 This research protocol does not include administration or manipulation of, or investigation of the
21 effects of, any pharmacological or therapeutic goods. However, in line with the pharmacovigilance
22 reporting requirements of the funding body, all survey data collected will be screened for adverse
23 events that may be associated with the funding body's products and, in the event of the research
24 team becoming aware of a potential adverse event, participants will be contacted (via email) and
25 invited to respond to additional questions about this event (e.g. medication brand name, dose and
26 timing, healthcare utilisation symptoms, other consequences). Non-response will not affect
27 participation in the study proper. De-identified information obtained about the event will be
28 submitted to the funder and, if relevant, the Australian Therapeutic Goods Administration.
29
30
31

32 Patient and public involvement

33 People with T2D were involved in the review and iterative refinement of the intervention content
34 and design. This involved cognitive debriefing interviews with six adults with T2D to review draft
35 content during intervention development, for which the findings and consequential refinements are
36 detailed elsewhere (33, 34). In addition, user ratings and qualitative feedback were provided by 13
37 pilot RCT participants who were allocated to the intervention (34). Refinements made to the
38 intervention following piloting included, for example, improving website navigation between barrier
39 webpages and the addition of 'print-friendly' downloadable PDF content (34). People with T2D were
40 not involved in the development of the study design, nor will they be involved in conduct of the
41 study or dissemination of the study findings.
42
43
44
45

46 Ethics and dissemination

47 This trial received ethical approval Deakin University Human Research Ethics Committee (Ref: 2020-
48 073). This study will be conducted in compliance with this protocol (version: SA-2017-11697; V2.2e
49 16 June 2020), which is registered with the Australian New Zealand Clinical Trials Registry (ACTRN:
50 12621000191897, registered Feb 23 2021). Note, this protocol was submitted for registration on 10
51 December 2020, prior to recruitment commencement (11 Jan 2021), though approved
52 retrospectively following enrolment of the first participant and prior to last participant enrolment.
53 Any changes to the protocol will be communicated to the human research ethics committee, funder,
54 and trial register. Protocol registration will be updated with any approved amendments to the
55 protocol, and protocol departures will be documented in any reports or manuscripts resulting from
56 this study.
57
58
59
60

Potential participants view the study plain language form online (Supplementary File 1) and must indicate consent (by ticking a box) prior to participating. Participants are free to withdraw from the study at any time, and for any reason, prior to completion of data collection.

The findings will be prepared for academic presentation at scientific meetings and in peer-reviewed journals. A lay summary of findings will be published on the research team's website and disseminated via e-newsletter. Study findings will also be reported to the funding body.

De-identified data may be made available, upon request, to the funding body.

Discussion

This randomised controlled trial will provide high quality evidence regarding the efficacy and acceptability of a novel, web-based resource: *'Is insulin right for me?'*. Using best-practice intervention development principles and evaluation guidance (33, 34), the intervention was designed to reduce salient psychological barriers to insulin, which are extremely common among people with T2D and associated with deleterious delay of insulin uptake (14, 44). To our knowledge, this study will be the first fully-powered randomised controlled trial conducted to test the impact of any intervention specifically designed to address salient psychological barriers to insulin among adults with T2D reporting some level of psychological insulin resistance.

The described study will provide evidence of the acceptability of this web-based resource among Australians with T2D who report some level of psychological insulin resistance, which may inform real-world implementation strategies and further refinements as required. A potential limitation of this trial is the expected low response rate and self-selection bias of the sample recruited via an invitation from the NDSS, which may not be representative of those most in need (i.e. those with a high HbA1c yet not at all willing to commence insulin) as well as linguistically diverse communities. Participants' demographic characteristics (e.g. gender, state/territory, language, country of birth) will be compared to the general Australian population of adults with T2D to examine the representativeness of the sample. If the intervention is shown to be efficacious, further research will be warranted to investigate its impact on timely insulin uptake (and consequently on HbA1c), as well as the feasibility of implementation in primary care settings among adults with T2D for whom treatment intensification is clinically indicated.

References

1. Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes care*. 2018;41(12):2669-701.
2. Gunton JE, Cheung NW, Davis TME, Zoungas S, Colagiuri S. A new blood glucose management algorithm for type 2 diabetes: A position statement of the Australian Diabetes Society. *The Medical Journal of Australia*. 2014;201(11):650-3.
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2015;38(1):140-9.
4. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. *Cardiovascular Diabetology*. 2015;14(1).

5. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. *New England Journal of Medicine*. 2008;359(15):1577-89.
6. Khunti S, Davies MJ, Khunti K. Clinical inertia in the management of type 2 diabetes mellitus: A focused literature review. *British Journal of Diabetes & Vascular Disease*. 2015;15(2):65-9.
7. Khunti S, Khunti K, Seidu S. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. *Therapeutic advances in endocrinology and metabolism*. 2019;10:2042018819844694.
8. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: A retrospective cohort study of more than 80,000 people. *Diabetes Care*. 2013;36(11):3411-7.
9. Furler J, O'Neal D, Speight J, Manski-Nankervis J-A, Gorelik A, Holmes-Truscott E, et al. Supporting insulin initiation in type 2 diabetes in primary care: results of the Stepping Up pragmatic cluster randomised controlled clinical trial. *bmj*. 2017;356:j783.
10. Manski-Nankervis J-A, Furler J, O'Neal D, Ginnivan L, Thuraisingam S, Blackberry I. Overcoming clinical inertia in insulin initiation in primary care for patients with type 2 diabetes: 24-month follow-up of the Stepping Up cluster randomised controlled trial. *Primary Care Diabetes*. 2017;11(5):474-81.
11. Zafar A, Stone M, Davies M, Khunti K. Acknowledging and allocating responsibility for clinical inertia in the management of Type 2 diabetes in primary care: a qualitative study. *Diabetic Medicine*. 2014.
12. Furler J, Spitzer O, Young D, Best J. Insulin in general practice: Barriers and enablers for timely initiation. *Australian Family Physician*. 2011;40(8):617-21.
13. Gabbay RA, Kendall D, Beebe C, Cuddeback J, Hobbs T, Khan ND, et al. Addressing therapeutic inertia in 2020 and beyond: a 3-year initiative of the American Diabetes Association. *Clinical Diabetes*. 2020;38(4):371-81.
14. Holmes-Truscott E, Furler J, Blackberry I, O'Neal DN, Speight J. Predictors of insulin uptake among adults with type 2 diabetes in the Stepping Up Study. *Diabetes Research and Clinical Practice*. 2017;133:204-10.
15. Wrzal PK, Bunko A, Myageri V, Kukaswadia A, Neish CS, Ivers NM. Strategies to overcome therapeutic inertia in type 2 diabetes mellitus: A scoping review. *Canadian Journal of Diabetes*. 2020.
16. Polonsky WH, Fisher L, Hessler D, Stuckey H, Snoek FJ, Tang T, et al. Identifying solutions to psychological insulin resistance: an international study. *Journal of Diabetes and its Complications*. 2019;33(4):307-14.
17. Or KY, Yip BH-K, Lau CH, Chen HH, Chan YW, Lee KP. Peer Education Group Intervention to Reduce Psychological Insulin Resistance: A Pilot Mixed-Method Study in a Chinese Population. *Diabetes Therapy*. 2018;9(1):113-24.
18. Kuo CR, Quan J, Kim S, Tang AHY, Heurman DP, Murphy EJ. Group visits to encourage insulin initiation: targeting patient barriers. *Journal of Clinical Nursing*. 2017;26(11-12):1705-13.
19. Holmes-Truscott E, Blackberry I, O'Neal DN, Furler J, Speight J. Willingness to initiate insulin among adults with type 2 diabetes in Australian primary care: Results from the Stepping Up Study. *Diabetes Research and Clinical Practice*. 2016;114:126-35.
20. Upsher R, Allen-Taylor M, Reece I, Chamley M, Ismail K, Forbes A, et al. Experiences of Attending Group Education to Support Insulin Initiation in Type 2 Diabetes: A Qualitative Study. *Diabetes Therapy*. 2020;11(1):119-32.
21. Holmes-Truscott E, Browne JL, Speight J. The impact of insulin therapy and attitudes towards insulin intensification among adults with type 2 diabetes: A qualitative study. *Journal of Diabetes and its Complications*. 2016;30(6):1151-7.
22. Holmes-Truscott E, Skinner TC, Pouwer F, Speight J. Negative appraisals of insulin therapy are common among adults with Type 2 diabetes using insulin: Results from Diabetes MILES – Australia cross-sectional survey. *Diabetic Medicine*. 2015:n/a-n/a.

23. Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: A systematic review. *Diabetic Medicine*. 2013;30(5):512-24.
24. Holmes-Truscott E, Pouwer F, Speight J. Further investigation of the psychometric properties of the insulin treatment appraisal scale among insulin-using and non-insulin-using adults with type 2 diabetes: results from diabetes MILES-Australia. *Health and Quality of Life Outcomes*. 2014;12(1):87.
25. Brod M, Alolga SL, Meneghini L. Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities. *The Patient: Patient-Centered Outcomes Research*. 2014;7(4):437-50.
26. Patel N, Stone MA, Hadjiconstantinou M, Hiles S, Troughton J, Martin-Stacey L, et al. Using an interactive DVD about type 2 diabetes and insulin therapy in a UK South Asian community and in patient education and healthcare provider training. *Patient Education and Counseling*. 2015;98(9):1123-30.
27. Horigan G, Davies M, Findlay-White F, Chaney D, Coates V. Reasons why patients referred to diabetes education programmes choose not to attend: a systematic review. *Diabetic Medicine*. 2017;34(1):14-26.
28. Brewster S, Bartholomew J, Holt R, Price H. Non-attendance at diabetes outpatient appointments: a systematic review. *Diabetic Medicine*. 2020.
29. Lui C-W, Coll JR, Donald M, Dower J, Boyle FM. Health and social correlates of Internet use for diabetes information: findings from Australia's Living with Diabetes Study. *Australian journal of primary health*. 2015;21(3):327-33.
30. van Vugt M, de Wit M, Cleijne WH, Snoek FJ. Use of behavioral change techniques in web-based self-management programs for type 2 diabetes patients: systematic review. *Journal of medical Internet research*. 2013;15(12):e279.
31. Abraham C, Michie S. A taxonomy of behavior change techniques used in interventions. *Health psychology*. 2008;27(3):379.
32. Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W, et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. *Annals of behavioral medicine*. 2013;46(1):81-95.
33. Holloway EE, Speight J, Furler J, Hagger V, O'Neal D, Skinner T, et al. 'Is Insulin Right for Me?' Development of a theory-informed, web-based resource for reducing psychological barriers to insulin therapy in type 2 diabetes. *BMJOpen* 2021; 11(9) :e045853.
34. Holmes-Truscott E, Holloway EE, Furler J, Hagger V, O'Neal D, Skinner T, et al. Feasibility and acceptability of a web-based intervention to reduce psychological barriers to insulin therapy among adults with type 2 diabetes: a two-armed pilot randomised controlled trial of 'Is Insulin Right for Me?'. *Australasian Diabetes Congress*; 11-13 November; Online2020.
35. Polonsky WH, Hajos TRS, Dain MP, Snoek FJ. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. *Current Medical Research and Opinion*. 2011;27(6):1169-74.
36. Australian Institute of Health and Welfare. *Diabetes prevalence in Australia: an assessment of national data sources*. . Canberra: AIHW; 2009.
37. Speight J, Browne JL, Holmes-Truscott E, Hendrieckx C, Pouwer F. Diabetes MILES - Australia (Management and Impact for Long-term Empowerment and Success): methods and sample characteristics of a national survey of the psychological aspects of living with type 1 or type 2 diabetes in Australian adults. *BMC Public Health*. 2012;12.
38. Cane J, O'Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. *Implementation science*. 2012;7(1):37.
39. Snoek FJ, Skovlund SE, Pouwer F. Development and validation of the insulin treatment appraisal scale (ITAS) in patients with type 2 diabetes. *Health and Quality of Life Outcomes*. 2007;5.

- 1
2
3 40. Polonsky WH, Anderson BJ, Lohrer PA, Welch G, Jacobson AM, Aponte JE, Schwartz CE.
4 Assessment of diabetes-related distress. *Diabetes Care*. 1995;18(6):754-60.
5 41. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire.
6 *Journal of psychosomatic research*. 2006;60(6):631-7.
7 42. Polonsky WH, Fisher L, Snoek F, Weinger K, Jelsovsky Z, Parkin CG, et al., editors. Evaluation
8 of the confidence in diabetes scale (CIDS-2) for patients with poorly controlled T2DM. American
9 Diabetes Association's 69th Scientific Sessions; 2009; New Orleans.
10 43. Fitzgerald JT, Funnell MM, Anderson RM, Nwankwo R, Stansfield RB, Piatt GA. Validation of
11 the revised brief Diabetes Knowledge Test (DKT2). *The Diabetes Educator*. 2016;42(2):178-87.
12 44. Odawara M, Ishii H, Tajima N, Iwamoto Y. Impact of patient attitudes and beliefs to insulin
13 therapy upon initiation, and their attitudinal changes after initiation: The DAWN Japan study.
14 *Current Medical Research and Opinion*. 2016;32(4):681-6.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgments

We thank the participants with T2D who participated in intervention development and piloting phases. We thank Victoria Yutronich (The Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria) for website design and technical support and Shaira Baptista (Deakin University) for research assistance.

Author contributions

EHT and JS conceived of the intervention and the described program of research. EHT and JS developed the study protocol, with input from EEH, HMH, JF, VH and TS. EEH, JS, TS and EHT led the development of the intervention, with contributions from JF, and VH. HMH calculated the sample size and developed the statistical analysis plan. EHT was responsible for drafting the manuscript, which EEH, HMH, JF, VH, TS and JS reviewed and contributed to. All authors approved the final manuscript.

Funding Statement

This work was supported by an instigator-sponsored-study grant from Sanofi-Aventis Australia Pty Ltd (Sanofi). Sanofi was not involved in the study design, and will not be involved in the collection, analysis or interpretation of the study data, but was given the opportunity to view the manuscript prior to submission. The decision to submit for publication was made independently by the authors. Sanofi will be allowed access to all de-identified data from the study for research and audit purposes, if requested. Costs associated with participation incentives, website development and data management were funded (in full, or partially) by the Australian Centre for Behavioural Research in Diabetes (ACBRD). In-kind support including project oversight was provided by the Investigator team. JS is supported by the core funding to the ACBRD provided by the collaboration between Diabetes Victoria and Deakin University. EHT was supported by the same plus a Deakin University Deans Research Postdoctoral Fellowship (2018-2020).

Competing interests statement

EHT has undertaken research funded by an unrestricted educational grant from Abbott Diabetes Care, AstraZeneca, and Sanofi; received speaker fees from Novo Nordisk and Roche to Australian Centre for Behavioural Research in Diabetes (ACBRD); and served on an advisory board for AstraZeneca. EEH has no conflicts of interest to disclose. JF has received unrestricted educational grants for research support from Roche, Sanofi, and Medtronic. TS serves on advisory boards for Novo Nordisk and Liva Health Care, and is currently on a EIT Health research grant held jointly with Roche Diagnostics. JS has served on advisory boards for Janssen, Medtronic, Roche Diabetes Care, and Sanofi Diabetes; her research group (Australian Centre for Behavioural Research in Diabetes [ACBRD]) has received honoraria for this advisory board participation and has also received unrestricted educational grants and in-kind support from Abbott Diabetes Care, AstraZeneca, Medtronic, Roche Diabetes Care, and Sanofi Diabetes. JS has also received sponsorship to attend educational meetings from Medtronic, Roche Diabetes Care, and Sanofi Diabetes, and consultancy income or speaker fees from Abbott Diabetes Care, AstraZeneca, Medtronic, Novo Nordisk, Roche Diabetes Care, and Sanofi Diabetes. All other authors have no conflicts of interest to declare.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

TIMEPOINT		STUDY PERIOD			
		Enrolment	Post-allocation		
		Screening	Baseline	Two weeks	Six months
ENROLMENT:					
	Informed consent	X			
	Eligibility screen	X			
	Randomisation		X		
INTERVENTIONS:					
	Intervention: Is insulin right for me?			→	
	Control			→	
ASSESSMENTS:					
Contact information	Name ^a , email address ^a	X		X	X
Pilot	Participation in the pilot study: yes/no ^a	X			
Recruitment	Referral method (e.g. NDSS invite)	X			
Demographics	Age ^a , gender ^a , country of residence ^a	X			
	Birth country, language, relationship status, employment, qualifications, postcode		X		
Diabetes	Diabetes type ^a , duration ^a , and management regimen ^a , prior use of injections ^a	X			
	Diabetes medications, most recent HbA1c, glucose monitoring behaviour		X		X
General health	Diabetes-related co-morbidities ^b , weight, height		X		
Clinical discussion of insulin therapy	Recall of prior clinical discussion and recommendation of insulin		X		X
Previous information about insulin therapy	What information about insulin have you read		X		
Psychological insulin receptiveness	Hypothetical willingness to commence insulin (35) ^a	X		X	X
Attitudes towards insulin	Insulin Treatment Appraisal Scale: ITAS (39)		X	X	X
Knowledge	Diabetes-specific: Diabetes Knowledge Test-True/False Version: DKT (43)		X		
	Insulin-specific knowledge: Study specific items		X	X	X
Diabetes-specific distress	Problem Areas In Diabetes: PAID (40)		X	X	X
Illness perceptions	Brief Illness Perceptions Questionnaire: BIPQ (41)		X	X	X
Diabetes-specific self-efficacy	Confidence In (type 2) Diabetes Self-management scale: CIDS-2 (or insulin version at follow-up for participants commenced insulin (CIDS-1) (42)		X	X	X
Diabetes management satisfaction	Study specific item		X	X	X
Resource use and acceptability	Resource access (yes/no). Reasons for not accessing; OR user rating scale (were questions answered?), free-text feedback (questions, likes/dislikes, improvements)			X	
Further comments	Free-text box for participant to provide further feedback.			X	X

Figure 1. Schedule of enrolment, interventions, and assessments.^a compulsory questions for participation. ^b Co-morbidities included: kidney disease, retinopathy, neuropathy, heart disease, stroke, vascular disease, sexual dysfunction, other (to be specified).

825x583mm (72 x 72 DPI)

Supplementary File 1. Plain Language Statement and Consent Form

Attitudes towards insulin therapy for people with type 2 diabetes

Plain Language Statement and Consent Form

Date: May 2020

Full Project Title: Development, Feasibility, and Efficacy of a Web-Based Intervention to Reduce Psychological Barriers to Insulin Therapy among Adults with Type 2 Diabetes (Stage 3: Full RCT)

Principal Investigators: Dr Elizabeth Holmes-Truscott and Professor Jane Speight, The Australian Centre for Behavioural Research in Diabetes (ACBRD), Deakin University

Associate Investigators: Dr Edith Holloway, ACBRD, Deakin University; Professor Timothy Skinner, Department of Rural Health, La Trobe University; Associate Professor John Furler, Department of General Practice, The University of Melbourne; Professor David O'Neal, St Vincent's Hospital, The University of Melbourne; and Dr Virginia Hagger, School of Nursing and Midwifery, Deakin University.

Dear participant,

You are invited to take part in this research project because you have type 2 diabetes, are aged between 18 and 75 years of age and take oral medication to manage your diabetes. In this study, we are investigating people's attitudes towards injecting insulin. We are also testing online resources about medications for type 2 diabetes. We want to know which resource(s) is the most useful for people with type 2 diabetes, who have questions or concerns about injecting insulin. Taking part involves exploring the web-based resource(s) and completing three online surveys over 6 months.

Below you can read further information about the study, so that you can decide if you would like to take part. Please take the time to read this information carefully. You can also print a copy of the [PDF](#) (*hyperlink to ethics approved version of the PLS inserted here*) or ask the study team for a hard copy to be sent to you. Ask the study team questions about anything you don't understand or want to know more about.

If you consent to taking part in this study, please click the box at the end of this webpage.

What is the purpose of this research?

Insulin is very effective for lowering blood glucose levels. Your doctor may recommend injecting insulin if other medications are unable to keep your blood glucose within your target range. However, people with type 2 diabetes may have concerns or questions about starting insulin. The purpose of this study is to test whether web-based resource(s) are useful for people with type 2 diabetes who have questions or concerns about starting insulin injections. The findings of this research may be used to inform what online resources about medications are available for people with type 2 diabetes in the future. We expect a total of 392 adults with type 2 diabetes will take part in this study.

Who can take part?

You can take part in this study if you:

- have type 2 diabetes and are currently taking oral medication to manage your diabetes. If you are currently, or have in the past, used self-administered injectable treatment for any illness or condition (for example insulin) you are NOT eligible to take part in the study.
- are between 18 and 75 years of age
- are able to read and speak English
- currently live in Australia
- have access to the internet and a computer (desktop, laptop) or tablet

You are not eligible to take part if you participated in the associated Pilot Study (between October and December 2019): Development, Feasibility, and Efficacy of a Web-Based Intervention to Reduce Psychological Barriers to Insulin Therapy among Adults with Type 2 Diabetes (Stage 2: Pilot Study).

What does taking part involve?

Taking part in this study will involve:

- Accessing and viewing a web-based resource(s) about medications for type 2 diabetes. You will be asked to do this at least once (and as many times you like) over a 2-week period.
- Completing three online surveys. The first survey will be upon entry to the study, the second survey will be emailed to you two weeks later and the third survey will be emailed to you at 6-months.
- Each survey will take 20 minutes to complete.
- The survey will include questions about you (age, gender, education), your diabetes, attitudes and knowledge about insulin, your understanding about diabetes and some questions about how diabetes makes you feel.
- You will also be asked to provide your name and email address. This is so we can link each of your surveys together and look at any changes in your responses over time. Any information you share with us will remain confidential.

After you have completed the first online survey on entry into the study, you will be allocated to one of two groups. You will receive a link to one of two web-based resources on insulin and type 2 diabetes. You have a 50% chance of being assigned to each group (like tossing a coin). You will have two weeks to explore the resource(s) allocated to you. We will send you an e-mail reminder during the two-week period to look at the resources. You will then be sent follow-up surveys at 2 weeks and 6 months.

Taking part in this study does not involve any change to your diabetes management or changes to the medications you take.

Who is conducting this study?

Deakin University is conducting this study with funding from Sanofi-aventis Australia Pty Ltd (Sanofi). The study is coordinated by researchers (Principal Investigators) at The Australian Centre for Behavioural Research in Diabetes (ACBRD), a partnership for better health between Diabetes Victoria and Deakin University. The Principal Investigators take responsibility for the study. Participants will only be contacted by the research team including the principal investigators, the study project manager or research assistant.

Are there any benefits for me personally?

People take part in studies like this for many reasons. For example:

- Taking part offers an opportunity to learn about and inform new diabetes research;
- Taking part offers an opportunity to think about your diabetes and reflect on your experiences;
- Taking part in research will help us to help other people with diabetes (either now or in the future).

In addition, participants who complete the study (i.e., access the web-based resource(s) and complete all three surveys) will be entered into a prize draw to win one of 20 \$100 department store gift cards that can be used at over 20 major retail stores in Australia.

Are there any risks to me?

No, we do not believe that this study will cause you any harm or put you at risk of harm. The study surveys include questions that may be sensitive or personal in nature (e.g. feelings about living with diabetes, income and employment status). However, we do not expect any question to cause you any distress. If you should become upset during the survey, you may stop completing the questions at any time. We encourage you to contact the researchers to discuss this. The researchers will be understanding and supportive. You have the right to refuse to answer any question that makes you uncomfortable.

If, as a result of participation, you do become distressed, you may wish to seek further information and support from beyondblue: Beyondblue – National Information Line Ph: [REDACTED] or visit: <http://www.beyondblue.org.au/>

If you have any questions about your diabetes following the survey, we encourage you to contact your health professional or to call the National Diabetes Services Scheme Helpline: [REDACTED].

Can I withdraw at any time?

Yes. You are free to withdraw from this study at any time. If you decide not to take part while completing an online survey, you can stop the survey and notify a member of the research team. Deciding not to take part (or to withdraw) will not affect your relationship with the ACBRD, Deakin University, Diabetes Victoria, or the study funder (Sanofi). If you withdraw from the study before, during, or immediately after you have completed the online surveys, we can remove any information you have shared from our analysis. However, once the study is closed your data will be de-identified and merged with other people's data. This means that you will not be able to withdraw the information you shared because we will not know which data are yours.

What will happen to my information?

Any information you share with us will remain strictly confidential. The survey data will be stored in a database via the Deakin University secure network. Only the research team will have access to the password protected data. Once we have collected all of the data and are ready to analyse the results, the survey responses will be downloaded and de-identified. These files will not include any identifying information about you. Identifiable information (for example your email, name) will be stored in a password-encrypted excel spreadsheet. Any personal details you share about yourself (e.g. surname, contact details) for the purposes of enrolling you into the study will be destroyed (electronic files to be deleted) after you have completed the final survey. Safety follow-up interview data will be stored electronically (i.e. audio files). All data will be stored in a secure Deakin University computer file accessible only by the ACBRD research team. In accordance with government requirements, your data will be stored for at least fifteen (15) years following the publication of the results and then destroyed by erasing electronic files and shredding paper copies.

1
2
3
4
5 The overall results of the study may be published or presented in academic journals, at conferences,
6 and in diabetes magazines and newsletters. Participants will be able to access any publications or
7 reports resulting from the study on the ACBRD website (www.acbrd.org.au). No-one will be able to
8 identify you from any of the information we publish or present. The study funder may request access
9 to the de-identified data. These data will not include any information that could be used to identify
10 you. We will take great care to protect your identity. Your privacy is very important to us.
11
12

13 **Who is funding this project?**

14
15 This project forms part of an Investigator Sponsored Study (SA-2017-11697) which is supported by
16 Sanofi-aventis Australia Pty Ltd (Sanofi). Sanofi has no involvement in the study design, data analysis
17 or interpretation and will not have any access to personally identifying information collected (e.g.
18 contact details). De-identified study data may be shared with Sanofi, including survey results. Your
19 personal and contact details will not be shared with Sanofi.
20

21 If you share with us (via the study surveys, e-mail or phone) any adverse events (safety issues)
22 associated with therapeutic goods (e.g. medications) during your involvement with this study, we are
23 required to report these to Sanofi. This could include any adverse events associated with the funder's
24 products. Therefore, all the data that we collect from you will be screened for adverse events that
25 may be associated with medications you take now or have taken in the past. In the event that you
26 report an adverse event, we will contact you and ask a small number of additional questions (e.g.
27 medication brand, dose, symptoms etc). If you decide not to answer the questions, this **will not affect**
28 **your participation in the study.**
29
30

31
32 In addition, the researchers will notify the Deakin University Human Research Ethics Committee
33 (DUHREC) of any adverse incidents, events, reactions that have a possible causal relationship with
34 this research.
35

36 **Has this study been approved by an Ethics committee?**

37
38 Yes. This study has been reviewed and approved by Deakin University's Human Research Ethics
39 Committee (DUHREC), reference number 2020-073.
40

41 **Who can I contact about this study?**

42
43 If you would like further information or have any questions about the study, please contact:

44 Dr Elizabeth Holmes-Truscott (e: [REDACTED] t: [REDACTED]),

45
46 Professor Jane Speight (e: [REDACTED] t: [REDACTED]), or

47
48 Dr Edith Holloway (e: [REDACTED] t: [REDACTED]), at the ACBRD.

49 To find out more about the work of the ABCRD, you may like to visit the website: www.acbrd.org.au.
50

51 If you have any complaints about any aspect of the project, the way it is being conducted or any
52 questions about your rights as a research participant, then you may contact:

53 The Human Research Ethics Office, Deakin University, 221 Burwood Highway, Burwood Victoria 3125,
54 Telephone: [REDACTED], email: [REDACTED]. Please quote project number 2020-073.
55
56
57
58
59
60

Consent Form

Please tick the box at the bottom of the page to indicate your agreement with each statement.

- I have read and I understand the Plain Language Statement.
- I freely agree to participate in this project according to the conditions in the Plain Language Statement.
- I have access to a copy of the Plain Language Statement and Consent form to print and keep.
- I understand and consent to completing three online surveys: at entry into the study, two-weeks and 6-months later. I will also be invited to explore web-based resources about type 2 diabetes and injecting insulin.
- I understand that if I report any adverse events (safety issues) associated with therapeutic goods (e.g. medications) I will be contacted and asked a small number of additional questions. If I decide not to answer the questions, this **will not affect my participation in the study.**
- I understand that the research team will not reveal my identity or personal details to anyone outside the research team, including where information is published or presented in any public form about this research study.
- I understand that the research team or the study funders may use the information I share in a closely related project, or an extension of the current research project, and that this information will be de-identified.

I have read and understood the information above and agree to take part in this study.

I am ready to start completing the Attitudes Towards Insulin Study

Withdrawal Form

To be used for participants who wish to withdraw from the project

Date: May 2020

Full Project Title: Development, Feasibility, and Efficacy of a Web-Based Intervention to Reduce Psychological Barriers to Insulin Therapy among Adults with Type 2 Diabetes (Stage 3: Full RCT)

Reference Number: 2020-073

*******IMPORTANT*******

Complete this form and return it to us only if you decide to WITHDRAW from the above-named study.

I wish to withdraw from participating in the study entitled ‘Development, Feasibility, and Efficacy of a Web-Based Intervention to Reduce Psychological Barriers to Insulin Therapy among Adults with Type 2 Diabetes (Stage 3: Full RCT)’. I do not want to take part in any additional study activities **and** I do not want the information I have already provided to be included in any analysis or study publications. I understand that withdrawing the information I have already provided will not be possible after completion of the second survey. I understand that withdrawing from the study will not adversely affect my relationship with any of the organisations conducting this study. I understand that withdrawing from the study will not affect the care or treatment I receive from any health professionals.

Participant’s name (please print)

Participant’s signature..... Date.....

Dr Elizabeth Holmes-Truscott
The Australian Centre of Behavioural Research in Diabetes
570 Elizabeth St, Melbourne, VIC 3000

T: [REDACTED]

E: [REDACTED]



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ItemNo	Description	Author response
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	Page 2, line 7
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	ACTRN12621000191897 Page 3, line 33
	2b	All items from the World Health Organization Trial Registration Data Set	See trial registration details. Page 3, line 33
Protocol version	3	Date and version identifier	This page (pg 2, line 13) & main text (pg 1, line 50)
Funding	4	Sources and types of financial, material, and other support	See Funding statement (pg 16, line 23)
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	This page (pg 2, line 20) & Authorship contribution statement (pg 16, line 12)
	5b	Name and contact information for the trial sponsor	Investigator sponsored study; Corresponding author (pg 2, line 2)

1			
2			
3			
4		5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
5			See Funding statement (pg 16, line 23)
6			
7			
8			
9		5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
10			Authorship contribution statement (pg 16, line 12); main text: Randomisation (pg 6, line 41) & Monitoring (pg 11, line 11)
11			
12			
13			
14			
15			
16	Introduction		
17			
18	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
19			Pg 4-5
20			
21			
22		6b	Explanation for choice of comparators
23			Pg 4, line 55 to pg 5, line 8
24	Objectives	7	Specific objectives or hypotheses
25			Pg 5, line 21-25
26	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
27			Pg 5, line 18-21
28			
29			
30			
31			
32	Methods: Participants, interventions, and outcomes		
33			
34	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
35			Pg 5, line 30-3
36			
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			

1			
2			
3			
4	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
5			
6			
7			
8	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
9			
10			
11		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
12			
13			
14			
15		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
16			
17			
18			
19			
20		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial
21			
22			
23	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
24			
25			
26			
27			
28			
29			
30			
31	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
32			
33			
34			
35			
36	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
37			
38			
39			
40			
41			
42			
43			
44			
45			
46			

1				
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	Pg 5, line 48 to pg 6, line 13. Pg 10, line 10-12
5				
6				
7	Methods: Assignment of interventions (for controlled trials)			
8	Allocation:			
9				
10				
11	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	Pg 6, line 41-48
12				
13				
14				
15				
16				
17				
18	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	Pg 6, line 48-56
19				
20				
21				
22	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	Pg 6, line 46-56
23				
24				
25	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	Pg 6, 48-56
26				
27				
28		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	Pg 6, 53-56
29				
30				
31				
32	Methods: Data collection, management, and analysis			
33				
34				
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	Pg 9, lines 5-42; pg 9, line 55 – pg 10, line 5; Figure 1 (pg 18)
		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	Pg 10, lines 6-25
	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	Pg 10, lines 27-35
	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	Pg 10/11, lines 38-9
		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	Pg 11, line 6-9
		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	Pg 10, line 46-57

Methods: Monitoring

bmjopen-2021-051529
 Downloaded from <http://bmjopen.bmj.com/> on 21 February 2022.
 Protected by copyright.

1				
2				
3				
4	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	P 11, line 11-30
5				
6				
7				
8				
9				
10				
11		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	NA
12				
13				
14				
15	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	P 11, line 21-30
16				
17				
18				
19	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	P 11, line 13-30
20				
21				
22				
23	Ethics and dissemination			
24				
25	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	P 11, line 49-50
26				
27				
28	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	P 11, line 56-60
29				
30				
31				
32				
33	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	P 12, line 3-6
34				
35				
36		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	NA
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

1				
2				
3				
4	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	Pg 9, line 56- pg 10, line 5; Pg 10, line 29-35
5				
6				
7				
8	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	Pg 16, lines 40-58
9				
10				
11	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	Pg 10, line 32-36; Pg 12, line 12.
12				
13				
14	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
15				
16				
17				
18	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	Pg 12, line 8-11
19				
20				
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	Pg 16, 12-21
25				
26				
27		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A
28				
29				
30	Appendices			
31				
32	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Appendix 1. (pg 19)
33				
34				
35	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	N/A
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				

bmjopen-2021-051529
 Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest.
 Protected by copyright.

1
2
3 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on
4 the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative
5 Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only